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Abstract 
 
The bacterium Pasteurella multocida is a gram-negative, non-spore-
forming, capsulated coccobacillus that lives an aerobic to facultative anaerobic 
lifestyle. P. multocida is a zoonotic pathogen that causes a myriad of diseases, 
including atrophic rhinitis, pasteurellosis, and dermonecrosis in a wide gamut of 
different host types. A major virulence factor produced by serotype D and some 
serotype A strains of P. multocida is P. multocida toxin (PMT), a 146-kDa 
modular protein deamidase that enters host cells via receptor-mediated 
endocytosis and manipulates intracellular signaling by constitutively activating 
the a-subunit of heterotrimeric G-proteins. This dissertation will focus primarily on 
two major unanswered questions regarding PMT and its action on host cells. 
First major question: During translocation of PMT from late endosomes into the 
cytosol of host cells, does the N-terminus of PMT (PMT-N) deliver its C-terminal 
cargo as an intact moiety, or as separate functional subdomains? Second major 
question: During cellular intoxication, by what molecular mechanism does PMT 
uncouple and subsequently downregulate G-protein-coupled receptor-
heterotrimeric Gaq-protein phospholipase C-b1 (GPCR-Gaq-PLCb1) signaling? 
These two questions are the basis for the generated hypotheses tested, 
experimental approaches taken, and sub-questions developed in this thesis. 
Here, I present data that contribute to answering these two major questions 
regarding delivery of C-terminal cargo by PMT-N into the host cytosol and its 
subsequent downregulation of Gaq-protein signaling in intoxicated cells. 
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To address the first question, we hypothesized that PMT-N delivers the C-
terminal cargo into the cytosol of host cells as an intact polypeptide comprised of 
amino acid residues 569-1285. Previous studies have shown that PMT-N 
facilitates host cell entry and cytosolic delivery of the C-terminal catalytic cargo 
from late endocytic vesicles. The putative cargo of PMT is a 78-kDa polypeptide 
of three discrete modular subdomains C1-C2-C3, for which there is a crystal 
structure available. Subdomain C1 harbors the membrane localization domain 
(MLD); C2 has an unknown function; and C3 contains the enzymatic deamidase 
activity that converts an active-site glutamine residue into glutamic acid in 
specific Gα-proteins. What is not clearly understood is whether the three C-
terminal cargo subdomains are delivered intact or undergo proteolytic cleavage 
between each discrete subdomain once translocated into the cytosol from late 
endosomes. In this dissertation, I present evidence that demonstrates that PMT-
N mediates the cytosolic delivery of its C-terminal cargo as a single-chain 
polypeptide, corresponding to C1-C2-C3 with the MLD. Additionally, the delivered 
cargo showed no indication of being cleaved between subdomains. I present 
evidence that shows that PMT-N can deliver C1-C2 alone, as well as C1-C2 and 
a truncated C3, which is in line with our previous work that PMT-N can deliver 
non-native cargo into the cytosol of host cells. This further supports the notion 
that receptor-binding and translocation modules are encompassed within PMT-N. 
Furthermore, I show that C1-C2 may facilitate the cytosolic delivery of the 
catalytic C3 subdomain in coordination with PMT-N. In addition, I present data 
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that refines the minimum C3 domain required for intracellular signaling activity as 
containing residues 1105-1278.  
To address the second question, we hypothesized that PMT uncouples 
and downregulates GPCR-Gaq-PLCb1 signaling by inducing, subsequent to 
activation, the redistribution and removal of Gaq subunits from the host plasma 
membrane. Previous studies have demonstrated that once inside the host 
cytosol, the initial activation of Gaq-PLCb1 signaling by PMT is subsequently 
followed by an uncoupling between of the GPCR and the a subunit of the Gaq 
protein, causing a significant decrease in downstream calcium and mitogenic 
signaling. What is not fully understood is the mechanism by which this 
uncoupling occurs. Preliminary studies in our laboratory indicated that Gaq/11, but 
neither Gas nor Gb were redistributed in the plasma membrane. Due to their high 
homology, it had not been discerned whether both Gaq and Ga11 or if only one of 
them is being redistributed and depleted from plasma membranes. In this thesis, 
I present data that PMT decreases over-expressed Gaq proteins in host plasma 
membranes and in detergent resistant membrane (DRM) fractions. I show that 
this membrane depletion of Gaq protein, but not Ga11, was dependent on PMT 
catalytic activity. The results from this study also indicate that in PMT-treated 
cells, Gaq is redistributed within the host cell plasma membrane, as evidenced in 
subcellular fractionation experiments where by Gaq moved from DRM fractions 
into more soluble membrane and cytosolic fractions. Conversely, PMT did not 
appear to change the levels of Ga11 levels, although Ga11 has been shown to be 
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a deamidation substrate for PMT. This strongly suggests that membrane 
depletion of Ga protein may be specific to certain Ga-proteins.  
The findings from these two studies reinforce that PMT-N serves as the 
cytosolic delivery vehicle for C-terminal cargo and demonstrate that its native 
cargo subdomains are delivered intact as C1-C2-C3 including the MLD. The 
findings in this study offer insights into the determinants that define the delivered 
cargo subdomains and the intrinsic nature of the cargo subdomains required for 
delivery, which furthers our understanding of the cytosolic cargo delivery process 
and may be applicable to other related A-B type toxins. Additionally, these 
findings show that PMT treatment induces the depletion of Gaq protein from the 
plasma membrane as a mechanism of downregulating GPCR-Gaq-PLCb1 
signaling, which may be a phenomenon that applies to other heterotrimeric Ga-
protein targets of PMT and other protein toxins that target Ga-proteins; thereby 
offering insights to the intoxication effects of PMT and related toxins in various 
cells types.  
Taken together both sets of findings have broader implications on how we 
understand the structural packaging and functioning of A-B type protein toxins; 
both in terms of their endosome-to-cytosol translocation and use as vehicles to 
deliver exogenous cytosolic cargos into host cells. These findings also offer 
insights on the inherent dual functions of toxins to affect signaling and alter cell 
fate to promote infection by their cognate organisms. Exogenous cargo delivery 
by different A-B type toxins opens doors for their potential use as 
pharmacological tools to deliver powerful novel therapeutics into unhealthy cells 
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as a way of treating or curing human illnesses. Understanding and defining the 
signaling dynamics and intracellular activity modulation of the activity cargos of 
these A-B toxins gives way for their potential use as the novel toxin-based 
cytosolic therapeutics, especially in cases where specific abnormal cell types 
may require targeted killing or inhibition of proliferation. In any case, such work 
as presented in this thesis may provide the information necessary to help fellow 
research scientists and physicians obtain the molecular tools needed to have a 
positive impact on human health.  
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Chapter 1 
When freedom is opportune: Pasteurella multocida  
clinical relevance and toxin mechanism of action 
 
 
1.1 Pasteurella multocida and disease 
 
Pasteurella multocida is a gram-negative, non-spore-forming, capsulated 
coccobacillus bacterium that has an aerobic to facultative anaerobic metabolism 
[reviewed in 54]. P. multocida is a zoonotic pathogen that causes a myriad of 
diseases in a wide gamut of different host types, including avian species, felines, 
canines, swine, rabbits, ungulates, humans, and non-human primates [reviewed 
in 52]. Clinically relevant serotypes of P. multocida encompass a putative 
virulence factor and virulence-associated profiles similar to that of other gram-
negative bacterial pathogens, including an intracellular-acting protein toxin, 
capsule, adhesins, endotoxin, sialidases, hyaluronidase, superoxide dismutases, 
iron-binding/transport proteins, and outer-membrane proteins, important for 
pathogenesis. In addition to the associated virulence factor profile, different 
isolates of P. multocida have resistance to a broad variety of antibiotics, including 
ampicillin, penicillin, amoxicillin, lincomycin, gentamicin, erythromycin, 
streptomycin, tetracycline, florfenicol, sulphaquinoxaline, and sulfamethoxazole-
trimethoprim [15, 24].  
The degree to which specific virulence factors and antibiotic resistance 
mechanisms are present in P. multocida varies by serotype [45]. This same trend 
continues in terms of particular disease states that are caused by or associated 
with specific serotypes of P. multocida in various animals and humans. In this 
chapter, distinct diseases and their causative serotypes and the major virulence 
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factor P. multocida toxin (PMT) responsible for a subset of diseases that are 
harmful and/or economically important to humans, will be highlighted. A model of 
PMT intoxication and unanswered questions regarding PMT action will be 
presented as the basis for the explored hypotheses and experimental 
approaches taken in this thesis. 
The specific disease states that are associated with P. multocida fit into 
two categories of causative modes of infection. One, where the disease 
syndromes are primarily caused by the bacterium P. multocida. Two, where the 
disease syndromes are caused, in part, by non-P. multocida associated factors 
that are not fully understood in tandem with P. multocida. Prevalent diseases in 
category one include avian cholera, hemorrhagic septicemia, atrophic rhinitis, 
and dermonecrosis in ungulates, swine, rabbits, and humans, respectively. 
Prevalent diseases in category two include lower respiratory tract infections and 
sporadic septicemias in ungulates. The aforementioned, category one disease 
states are summarized below [reviewed in 52, 54]. 
Avian Cholera 
Avian cholera, also known as fowl cholera, is a systemic disease that 
affects all known species of wild and farmed birds, including chickens, turkeys 
and ducks, which are important economically to the agricultural industry. The 
designation “cholera” is a bit of a misnomer as the disease is caused by type A, 
F, and infrequently type D, serotype strains of P. multocida, where no Vibrio 
cholerae strains are involved, but are instead associated with symptoms and 
reservoir type for wild birds that overlaps with P. multocida. Virulent strains of P. 
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multocida colonize the upper respiratory tract and subsequently disseminate 
lower into the lungs, and in the terminal stages of disease, enter the bloodstream 
to cause bacteremia. Symptoms include lethargy, ruffled feathers, loss of 
appetite, lung lesions, coughing, diarrhea, nasal discharge, fever, swollen wattles 
and combs, arthritis, and sudden death. These symptoms can last up to several 
days before death. Strains of P. multocida associated with avian cholera do not 
produce any known toxins, but instead produce other classic virulence factors, 
such as capsule, lipopolysaccharide, iron acquisition proteins, fimbriae, 
filamentous hemagglutinin, and sialic acid uptake systems, which are thought to 
play roles in the establishment of infection and disease progression [reviewed in 
52]. 
Hemorrhagic Septicemia 
Hemorrhagic septicemia (HS) is a systematic disease that is thought to 
likely affect all P. multocida-infected hoofed animals [reviewed in 9, 52], including 
cattle, swine, buffalo, and deer that are important economically to food 
production industries. HS is caused primarily by serotypes B and E and rarely 
type A strains [46]. These infectious strains enter the body by way of the tonsils 
through engulfment by macrophages. After escaping the macrophage, they 
proliferate in the soft tissue of tonsils, and the bacteria that hitch a ride within the 
macrophages are carried to the lymph nodes. Subsequently, they spread to the 
surrounding tissue and establish infection. The bacteria divide quickly and cause 
local edema and necrosis. Bacteremia occurs soon after tissue necrosis, where 
endotoxic shock plays a role in the terminal stages of disease [19, 20]. 
 4 
 
Symptoms include fever, loss of appetite, nasal discharge, excessive salivation, 
strenuous breathing, and internal tissue, subcutis, and muscle lesions among 
other types, followed by recumbence and death [reviewed in 52]. Though type A 
strains are recovered in a small number of cases of HS, no characteristics of the 
disease are attributed to any known toxin produced by P. multocida. Virulence 
factors associated with HS disease progression include capsule, fimbriae, and 
filamentous hemagglutinin [reviewed in 52, 54].  
Atrophic Rhinitis 
Atrophic rhinitis is characterized by loss of the turbinate bone structure in 
the snout of swine [reviewed in 55]. Accompanying symptoms include other facial 
abnormalities, such as distorted upper jawbones and deviation of the nasal 
septum. Additionally, stunted growth in piglets is commonly associated with the 
disease [11]. The syndrome occurs in wild boar and domesticated pigs, but has 
also been reported in goats, cattle, and rabbits [reviewed in 52]. The ailment is 
caused by toxinogenic serogroup type D, and some type A strains of P. 
multocida, where the toxin PMT is responsible for all symptoms and outcomes of 
the disease [10] These PMT-producing serotype D and A strains are able to 
colonize the upper respiratory tract, usually with the presence of Bordetella 
bronchiseptica, to establish infection [8, 39]. The PMT is released into the nasal 
and upper respiratory tract mucosa, where it enters the epithelium, subsequently 
reaches bone cell progenitors, and causes differentiation of these cells into bone 
absorbing osteoclasts, leading to bone destruction [49, 50]. No other known 
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virulence factors, including fimbriae, are important for the establishment of 
symptoms that cause atrophic rhinitis [reviewed in 52, 54]. 
Dermonecrosis in Humans 
Though the exact mechanism of pathogenesis is poorly understood, P. 
multocida-induced dermonecrosis in humans in characterized as an opportunistic 
infection that results in acute death of surrounding flesh from where the organism 
has established infection. Usually this occurs in subcutaneous tissue and along 
fascial planes of the skin. The syndrome usually occurs after humans suffer a 
bite from domesticated cats or dogs; being especially common in the elderly and 
those who are immunocompromised. When determined, serogroup A and D 
strains of P. multocida are the causative organisms reported [reviewed in 52, 54]. 
Additionally, intradermal injection of PMT from P. multocida serotype D causes 
skin lesions [35]. Hence, PMT is strongly implicated in disease progression. No 
other virulence factors have been shown to play a role in dermonecrosis 
[reviewed in 52, 54].   
Potential Carcinogen for Humans 
Certain bacterial pathogens, such as Salmonella, Chlamydia, and 
Helicobacter, have been linked to cancer in humans. Thus, it is speculated that 
other pathogens may have some link to oncogenesis during infectious exposure. 
Since many bacteria can produce factors, such as toxins, that may alter or 
modulate intracellular signaling pathways known to be important in cancer cell 
signaling, investigation by researchers into these potential carcinogenic 
properties of these bacteria is underway. P. multocida is one of the bacteria 
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suspected to have the ability to cause cancer in humans due to its production of 
PMT by toxinogenic strains. PMT is known to affect three heterotrimeric G-
protein signaling pathways: Gq/11, G12/13, and Gi/o, all of which have been linked or 
shown to be important for tumorigenesis through affecting the activity of protein 
kinase C, Rho, focal adhesion kinase, c-jun, E-cadherin, Wnt, b-catenin, Cox, or 
Src, each of which have been implicated in cancer formation [reviewed in 17, 27].  
Although P. multocida and PMT have not been directly shown to cause 
cancer in infected patients, and no long-term correlative studies have been 
published to show a linkage between instances of cancer in previously infected 
patients, researchers have promoted a level of awareness of the associated 
carcinogenic health risks with exposure to bacterial toxins such as PMT 
[reviewed in 17, 27, 28, 44]. Indeed, time of exposure, cell types exposed, 
magnitude of signaling, and predisposing health factors may play a role in 
oncogenesis, or lack thereof, as various cell lines have been shown to be either 
proliferative or apoptotic when intoxicated with PMT [reviewed in 27]. Although 
PMT acts at the protein level with sustained activation of mitogenic signaling, 
PMT has not be shown to cause any higher rates of genetic mutations. Hence, it 
is unclear if PMT effects may be short-lived and inconsequential in terms of 
cancer formation when cellular differentiation or transformation is not reached in 
intoxicated cells. Therefore, long-term or chronic exposure to PMT, given its 
ability to affect cell transforming pathways, may be more important and present 
the most significant risk to predisposing humans to developing cancer [reviewed 
in 17, 27]. 
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1.2 Pasteurella multocida toxin as a modular AB-type toxin and comparison 
with other dermonecrotic deamidase toxins 
 
Many proteins are characterized as having functional or discrete domains, 
called modules. These discrete physical domains and subdomains of various 
proteins and enzymes, each having a specific function that works singularly or in 
tandem to perform a biochemical job, represents the basis of how researchers 
have come to perceive many proteins toxin as being “modular.” In any given 
multidomain protein, each individual domain or subdomain represents distinct 
modules that can function independently from one another. These modules are 
considered building blocks that can be experimentally separated into their 
individual units and still retain their biological activity. In some cases, they can be 
pieced back together in different molecular arrangements, have internal and 
terminal deletions, be non-natively attached to other modules and proteins, and 
still retain their full-to-partial functions. Minimally, these non-native modules are 
able to exist linked together as stable proteins that can be tested to tease out 
unknown intracellular roles of sub-domains. On the other end of the spectrum, 
using different intact combinations of these modules can unmask the potential to 
create novel proteins for use in different applications, such as in molecular 
diagnostics and therapeutics [reviewed in 18, 31, 32]. 
PMT harbors deamidase activity and acts upon heterotrimeric G-proteins 
once it has entered host cells via receptor-mediated endocytosis. This toxin is 
composed of two major, functional parts within a single polypeptide chain of 
1,285 amino acids: an activity (A) part and a binding (B) part. Hence, the toxin is 
termed an AB-like protein toxin. The B part, termed PMT-N, is comprised of 
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residues 1-568 and is thought to be composed of two functional subdomains: the 
binding domain responsible for target cell recognition and the translocation 
domain responsible for transporting the cargo across cell membranes. The 
binding subdomain brings the A domain to the surface of the host cell by binding 
to its cognate receptors. Afterwards, the host cell engulfs the toxin and the 
translocation subdomain escorts the A domain into the cytosol of the host 
[reviewed in 56]. As of yet, no crystal structure of PMT-N is available to confirm 
these as two physically discrete subdomains, but sequencing and mutagenesis 
studies have strongly implicated them to reside minimally within amino acid 
residues 1-505 of PMT-N [3, 4]. 
The A domain is responsible for the intracellular activity of the toxin. This 
domain is composed of residues 569-1285, also known as the C-terminus of 
PMT (PMT-C). As evidenced by the crystal structure of residues 575-1285 of 
PMT-C [25], the A domain contains three physically discrete subdomains: C1, 
C2, and C3 (Figure 1.1). Amino-acid residue 575-719 make up the C1 
subdomain that contains a membrane localization domain (MLD) between 
residues 589-668, which forms four alpha-helical bundles that are thought to 
target the entire A domain to the host cell plasma membrane, where it can 
interact with its heterotrimeric G-protein substrates [22]. C2 spans residues 720-
1104 and currently does not have any known function, yet some have speculated 
that it may act as a secondary co-enzyme in helping with molecular recognition of 
substrates. Indeed, C1-C2 shows significant sequence and modelled structural 
homology to the effector protein DUF5 of MARTX toxin, which has cytotoxic 
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activity, yet C1-C2 of PMT alone is not cytotoxic [2]. In critically analyzing the 
crystal structure of PMT-C (Figure 1.1), one can also speculate that C2 may 
interact with C1 to help stabilize the A domain overall. C3 harbors the deamidase 
activity of the A domain that is driven by its cysteine-histidine-aspartate catalytic 
triad to convert specific amide groups of glutamine residues into glutamic acids in 
the active sites of target proteins: Gaq/11, Gai/o, and Ga12/13 families of 
heterotrimeric G-proteins [reviewed in 36, 38]. 
PMT belongs to the family of modular toxins that include the cytotoxic 
necrotizing factor (CNF) toxins from Yersinia sp. (CNFy) and E. coli (CNF1, 
CNF2, and CNF3), and the dermonecrotic toxin (DNT) from Bordetella sp. [53]. 
These toxins are grouped as dermonecrotic toxins based on their ability to cause 
necrosis of the skin and subcutaneous tissue. DNT and the CNF toxins 
intracellularly affect similar signaling pathways through their action on 
downstream effectors of the small G-protein RhoA and associated family 
members that lead to cytopathic effects in intoxicated cells.  
DNT is a single polypeptide chain, A-B type protein toxin comprised of 
1,464 amino acids with a predicted molecular weight of ~160 kDa. The N-
terminus of DNT is composed of a 54 amino acid receptor-binding domain, where 
the first 2-30 amino acids are crucial for host cell binding. The catalytic activity of 
DNT resides at the C-terminus, between residues 1165-1464. Once the toxin has 
gained entry into the host cytosol via dynamin-mediated endocytosis, DNT is 
subjected to furin-dependent proteolytic processing and undergoes acidification-
dependent translocation into the cytosol, where it constitutively activates the Rho 
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family of small GTPases via trans-glutamination (deamidation and polyamination) 
at specific glutamine residues [13, reviewed in 14, 23, 33].  
The CNFs are single-chain, AB-type protein toxins of about 1,014 amino-
acids in length with a molecular size of ~114 kDa. The N-terminus of CNF1, 
based on the reported cleavage site of the C-terminus, spans residues 1~540 
and is predicted to be ~59 kDa. The receptor-binding domain resides within the 
N-terminus between residue 53-190, and the translocation domain harbors a 
putative helix-turn-helix motif (residues 350-412) that is thought to be important 
for cytosolic delivery of the C-terminal cargo [12, 26, 29, 40, 48]. The C-terminus 
of CNF1 that is reported to be translocated into the cytosol of intoxicated cells is 
approximately 55 kDa [26]. The C-terminal catalytic subdomain is comprised of 
residues 720-1014 [6] (see Figure 1.1). Additionally, CNF1 has a putative 
secondary co-receptor-binding subdomain between residues 683-730 [34]. Once 
the C-terminal cargo gains access to the cytosol via receptor-mediated 
endocytosis, the catalytic subdomain translocates into the cytosol and activates 
the Rho family of small GTPases via deamidation of specific active site glutamine 
residues [30, 47] 
 
1.3 Pasteurella multocida toxin host cell binding, endocytosis, and 
cytosolic translocation 
 
The gene encoding PMT is located on a relatively low G+C content 
lysogenic bacteriophage that is integrated into the bacterial genome within a 
tRNA gene [41]. PMT is constitutively expressed in P. multocida and is localized 
to the cytoplasm. PMT has no known signal sequence for extracellular secretion 
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and is not secreted in vitro from intact living P. multocida cells [reviewed in 55]. 
How PMT is released from the bacteria is not well understood, yet it is 
speculated that during a lytic phage cycle event or an attack by the host immune 
response that lyses cells during infection, PMT is then expelled from the bacteria.  
Once released, PMT is able to bind the surface of a wide variety of 
endothelial and epithelial host cell types. PMT preferably binds to a combination 
of membrane phospholipids phosphatidylcholine and sphingomyelin, and a 
trypsin-sensitive protein receptor at the surface of host cells [5]. This binding 
triggers endocytosis: engulfment of the toxin and receptor into an endosome. The 
endosome is trafficked in an Arf-6-dependent manner to the lysosomal 
degradation pathway, where it undergoes acidification [43].  
Translocation of PMT from endosomes into the cytosol is not well 
understood, but the process is acidification dependent [42, 43]. The acidification 
of the internal endosomal compartment is thought to cause a conformational 
change in the toxin, where the N-terminal translocation subdomain in the 
predicted negatively charged helix-loop-helix region (residues 402-457) is 
protonated, thereby neutralized, and inserts into the endocytic membrane [3]. 
This membrane insertion is thought to lead to pore formation in the endosome, 
where the C-terminal catalytic domain of PMT is then escorted through the 
membrane and into the cytosol. PMT, via its putative MLD, localizes to the 
plasma membrane and affects its heterotrimeric G-protein targets (Figure 1.2).  
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1.4 Pasteurella multocida toxin and heterotrimeric G-protein signaling 
 
Mammalian heterotrimeric G-protein signaling regulates downstream 
signaling pathways through the transduction of extracellular stimulation from their 
plasma membrane heptahelical receptor to most immediate downstream effector 
proteins. The components of a typical heterotrimeric signaling complex involves a 
transmembrane heptahelical G-protein-coupled receptor (GPCR), the 
heterotrimeric G-protein, and its effectors, which may be plasma membrane 
bound or cytosolic. The G-protein is composed of 3 subunits: α, β, and γ, which 
are tethered to the plasma membrane via palmitoylation or myristylation of the α-
subunits or prenylation of the γ-subunits, depending on the type of G-protein. 
Inactivated GDP-bound, heterotrimeric G-proteins interface with the GPCR. 
When the GPCR is bound by an agonist, it is activated and undergoes a 
conformational change that in turn causes the GPCR to act as a guanine 
nucleotide exchange factor (GEF) to stimulate exchange of GDP for GTP in the 
α-subunit. The GTP-bound α-subunit is thought to dissociate from the GPCR and 
the βγ complex. The α-subunit activates the effector of one signaling pathway 
and the βγ-subunit complex interacts with another signaling pathway. Interaction 
of the α-subunit with the effector subsequently causes the effector to act as a 
GTPase-activating protein, which in turn results in the hydrolysis of GTP to GDP 
in the α-subunit. Following GTP hydrolysis, the GDP-bound α-subunit 
reassociates with βγ-subunits and the GPCR and performs the signal 
transduction again if the agonist is still present. Therefore, it can be said that 
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heterotrimeric signaling is cyclical and reversible (Figure 1.2). If the agonist is 
removed, the complex can return to a resting state [reviewed in 7, 51].  
Heterotrimeric G-proteins are grouped into four family types, depending on 
the biological activity of their immediate downstream effectors. Of the four known 
heterotrimeric G-protein families, Gq/11, G12/13, Gi/o, and Gs, PMT activates three of 
them; Gq/11, G12/13, and Gi/o. It does so in a direct manner independent of the 
GPCR by specifically deamidating an active-site glutamine residue in the switch 
II region of preferably monomeric α-subunits of Gq, Gi, and G13, specifically at 
residue Q209 of Gaq, Q205 of Gai, and Q226 of Ga13 [21, 36, 37]. This 
modification results in conversion of these glutamine residues into glutamic acid 
and renders the Ga-protein into a constitutively active form that causes constant 
activation of downstream effector signaling.  
Activation of Gaq leads to activation of PLCβ1, which hydrolyzes 
phosphatidylinositol-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 
trisphosphate (IP3), leading to the activation of protein kinase C (PKC), the MAP 
kinase cascade, and mobilization of intracellular calcium pools. Activation of Ga13 
and Gaq leads to activation of Rho GEFs that in turn activate the Rho family of 
GTPases. Subsequent activation of Rho causes actin cytoskeleton remodeling, 
cell rounding, and affects cell migration. Activation of Gai leads to inhibition of 
adenylate cyclase, which results in a decrease in the second messenger cyclic-
AMP, and therefore downregulation of cyclic-AMP-dependent pathways 
important for cellular metabolism [reviewed in 7, 16].  
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In terms of overall cellular effects, PMT is a potent mitogen able to cause 
pleiotropic effects with cellular consequences likely dependent upon cell type.  
PMT-induced constitutive action of these G-protein pathways leads to complex 
abnormal signaling regulation, causing unchecked cell growth, proliferation, and 
differentiation, and in some cases cell death [reviewed 56, 58]. Ultimately, these 
adverse functions can prove to be detrimental to the host organism. 
 
1.5 Aims: Addressing questions regarding PMT action 
The purpose of this thesis is to focus on two major unanswered questions 
regarding the protein structural organization and function of PMT and its action 
on host cell G-protein signaling. The first major question: During translocation of 
the PMT from late endosomes into the cytosol of host cells, does the N-terminus 
of PMT (PMT-N) deliver its C-terminal cargo (C1-C2-C3) as an intact moiety or 
as separate functional subdomains? The second major question: During cellular 
intoxication, by what molecular mechanism does PMT uncouple and 
subsequently downregulate GPCR-Gaq-PLCb1 signaling? As it stands, the 
model of PMT intoxication before the investigation set forth in this thesis, which 
encompasses binding, entry, cytosolic translocation, activation of Gq-protein 
signaling, and subsequent uncoupling, is as follows: Upon PMT binding to the 
cell-surface receptors, full-length PMT is taken up by endocytosis and is 
trafficked from early to late endosomes. Upon the lowering of the endosomal pH, 
the acidification of PMT-N triggers conformational changes and membrane 
interactions that facilitate the translocation of cargo across the membrane and 
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into the cytosol, where the native catalytic C3 subdomain may activate its target 
Gα subunit through deamidation. Subsequent to the initial activation of the Gα 
subunit and its downstream effector, the Gα subunit is uncoupled from the GPCR 
and is modified such that it is unable to further activate the effector or reassociate 
with the Gβγ-subunits and the GPCR, and therefore the signaling pathway is 
irreversibly down-regulated or uncoupled (Figure 1.3). 
It is understood that PMT-N facilitates host cell entry and cytosolic delivery 
of the C-terminal catalytic cargo from acidified endocytic vesicles [42, 43]. For the 
native toxin, the expected C-terminal cargo is a 78-kDa polypeptide made of 
three discrete modular subdomains C1-C2-C3. What is not clearly understood is 
whether the three C-terminal cargo subdomains are delivered intact, separately, 
or undergo proteolytic cleavage between each discrete subdomain once 
translocated from late endosomes. The second chapter of this thesis attempts to 
address this major question and also investigates the ability of PMT-N to deliver 
modified native and exogenous cargos into the cytosol of host cells and to further 
refine the minimal C3 subdomain required for intracellular signaling activity.  
To examine which subdomains are delivered into the cytosol and the 
degree of their intactness, I generated full-length and various truncated variants 
of PMT with affinity tags (HA-tags) at the C-terminus for ease in purification using 
affinity chromatography. I utilized subcellular fractionation and immunoblot 
analysis to track the intracellular localization of the full-length toxin protein and 
translocated toxin fragments after host cell uptake. This would help us to 
determine if the delivery process involves the translocation of full-length or 
 16 
 
cleaved protein product into the cytosol and if delivery of the activity domain 
occurs by a different mechanism. Additionally, I generated synthetic HA-tagged 
protein markers comprising the predicted C-terminal cargos of PMT, including the 
subdomains C1-C2 and C1-C2-C3, with and without the MLD. This would help us 
confirm that any delivered cytosolic moiety is indeed intact and of the expected 
size. 
Previously, our laboratory had defined the minimal domain required for 
catalytic activity of PMT from the N-terminal end of the C3 subdomain to be at 
position 1105 [1]. To further refine the minimal C3 subdomain required for 
intracellular activity, we sought to define the minimal C-terminal residues required 
for signaling activity. To examine this, in collaboration with Elizabeth E. 
Haywood, I generated truncated variants of PMT at the C-terminus and tested 
their signaling output in cultured HEK-293T cells utilizing the serum response 
element-luciferase (SRE-luciferase) reporter assay. This would allow us to 
ascertain the minimal PMT C-terminus of C3 domain required to stimulate 
intracellular signaling. 
Additionally, our laboratory and others have shown that variants of PMT-N 
(amino acid residues 1-505 or 1-568) are stable proteins and possess the ability 
to bring exogenous cargo into the intracellular space of host cells and cause 
cellular cytotoxicity, including when fused to membrane impermeable bacterial 
toxins [1, 4, 43]. What was not clear in these studies was whether PMT-N was 
delivering the exogenous cargo into the cytosol intact or if it was being done in an 
endosomal acidification-dependent manner. To examine if PMT-N is able to 
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deliver modified native cargo, I generated, in collaboration with Elizabeth E. 
Haywood, recombinant proteins of PMT-N fused to C-terminal subdomains of 
C1-C2, C1-C3, C2-C3, or C3 alone. We used a combination of methods, 
including subcellular fractionation and immunoblot analysis, SRE-luciferase 
reporter assay, and treatment with acidification and actin polymerization 
inhibitors, to assess whether or not PMT-N could deliver the C-terminal cargo 
into the cytosol in an acidification-dependent manner. Overall, the results from 
these studies allowed us to gain insights into the PMT cargo-delivery process.  
The third chapter of this thesis addresses the second major question. It 
was previously shown by our laboratory that PMT first strongly activates Gaq-
PLCb1 signaling, but this is subsequently followed by an uncoupling of the 
GPCR, the G-protein a and bg subunits, and their effector proteins, causing a 
significant decrease in downstream calcium and mitogenic signaling [57]. What 
was not fully understood is the mechanism by which this uncoupling and 
downregulation occurs. We predicted that this might occur by the action of PMT 
on Gaq subsequently inducing the loss of the Gaq protein from the host plasma 
membrane, including detergent resistant membrane (DRM) domains. To examine 
this, in collaboration with Shuhong Luo and Mengfei Ho, we used an 
experimental system of cultured mammalian cells and transient DNA 
transfections with Gaq or Ga11, in tandem with cellular fractionation, density 
gradient analysis, and immunoblot visualization to monitor the localization and 
distribution of endogenous and overexpressed G-proteins in response to PMT 
treatment. 
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Additionally, we attempted to pinpoint the molecular signal for the 
induction of G-protein depletion from membranes and redistribution. We 
hypothesized, that the presence of constitutively active Ga-proteins served as 
substrates for removal from the plasma membrane. To address this, we used the 
aforementioned experimental system and monitored the levels of exogenously 
expressed, constitutively active Ga-proteins in the presence or absence of PMT. 
The results from these studies allowed us to gain insights into the modulation of 
cell signaling by PMT. 
Collectively, these studies have larger implications for how we interpret 
the molecular packaging and functioning of A-B type bacterial toxins; both in 
terms of their translocation and utilization as vehicles to deliver exogenous 
cytosolic cargos into target cells. These findings also offer insights on the 
inherent dual functions of exotoxins to affect intracellular signaling and cell fate to 
promote infection by their cognate organism. Examples of such work in this 
thesis may provide the information necessary to help fellow researchers obtain 
the molecular tools needed to have a positive impact on human health.  
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1.6 Figures 
 
 
Figure 1.1. Crystal structures of PMT and CNF1. Shown is the crystal 
structure of PMT C-terminus (amino acid residues 575-1285) rendered from PDB 
2EBH and CNF1 C-terminus (amino acid residues 720-1014) rendered from PDB 
1HQ0 in PyMOL. For PMT: C1 subdomain is depicted in blue (residues 575-719). 
C2 subdomain (amino acid residues 721-1104) is depicted in green. C3 catalytic 
subdomain is depicted in magenta (residues 1105-1262) + yellow (residues 
1263-1285). For CNF1: Catalytic domain is depicted in magenta (amino acid 
residues 720-1014). 
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Figure 1.2. Model of PMT binding, endocytosis, and cytosolic delivery. Full-
length PMT binds the cell-surface receptors and is taken up by endocytosis and 
is trafficked from early to late endosomes. Acidification of the endosomal 
compartment of triggers a conformational change in PMT-N and membrane 
interactions that facilitate the translocation of cargo. The translocated C1-C2-C3 
is then localized to the plasma membrane, bringing the catalytic subdomain C3 in 
proximity to its target Gα subunit.
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Figure 1.3. Model of typical heterotrimeric G-protein signaling. The GPCR 
when bound by an agonist, is activated and undergoes a conformational change 
that in turn causes the GPCR to act as a guanine nucleotide exchange factor. 
This stimulates exchange of GDP for GTP in the α-subunit. The GTP-bound α-
subunit dissociates from the GPCR and the βγ complex. The α-subunit activates 
the 1st effector of the signaling pathway. Interaction of the α-subunit with the 
effector subsequently causes the effector to act as a GTPase-activating protein. 
This results in the hydrolysis GTP into GDP in the α-subunit. Following GTP 
hydrolysis, the GDP-bound α-subunit reassociates with βγ-subunits and the 
GPCR.  
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Figure 1.4.  Model of PMT Intoxication and Effects on G-Protein Signaling. 
Model of PMT intoxication to be tested. Full-length PMT binds the cell-surface 
receptors and is taken up by endocytosis and is trafficked from early to late 
endosomes. Acidification of the endosomal compartment triggers a 
conformational change in PMT-N and membrane interactions that facilitate the 
translocation of cargo C1-C2-C3 into the cytosol. 1st major question of intactness 
and proteolytic processing. C3 activates the α-subunit of the G-protein signaling 
pathway and in turn activates the 1st effector of the pathway. The α-subunit is 
subsequently uncoupled from the GPCR and the signaling pathway is 
downregulated. 2nd major question of uncoupling and downregulation 
mechanism. 
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Chapter 2 
Escape to the interior as one piece: Cytosolic delivery of multi-
domain cargos by the N-terminus of Pasteurella multocida toxin 
 
2.1 Introduction 
 
Type D and A strains of Pasteurella multocida produce the 146-kDa 
modular protein toxin (PMT), which is the etiological agent responsible for 
dermonecrosis, atrophic rhinitis and pasteurellosis animals and humans 
[reviewed in 22]. PMT gains entry into host cells via receptor-mediated 
endocytosis through binding to phosphatidylcholine, sphingomyelin, and an as-
yet-unknown trypsin-sensitive protein partner at the surface of host cells [4]. After 
binding and uptake, PMT’s toxic cargo is delivered from late endosomes into the 
cytosol in a pH-dependent manner [19, 25]. PMT’s catalytic cargo modulates 
downstream signaling pathways [reviewed in 23, 24] through deamidation of 
active site Gln residues in target Gα subunits that results in them being 
constitutively activated [14, 27]. However, the resulting activation of Gαq 
mediated signaling is followed by downregulation through membrane 
redistribution and depletion of the Gαq-protein [6].  
Discrete functional domains mediate the binding and entry of PMT into 
host cells, followed by cytosolic delivery of the components responsible for 
intracellular activity [reviewed in 25]. The structure of the C-terminus of PMT 
(residues 569-1285) [13], which harbors the intracellular toxic activity, revealed 
three distinct subdomains (Figure 2.1) that serve as functional modules: C1 (575-
719) with membrane targeting function, where amino acid residues 589-668 
comprise the putative membrane localization domain (MLD) [10, 12]; C2 (720-
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1104) with as-yet unknown function; and C3 (1105-1285) with the minimal 
catalytic domain having Gln-deamidase activity [1, 17].  
There is no crystal structure available for the N-terminus of PMT (PMT-N), 
yet several studies have demonstrated that PMT-N harbors the functional 
domains responsible for cell binding, cellular uptake, trafficking to endosomes, 
membrane translocation, and cytosolic cargo delivery [2, 3, 4,18,19]. Additionally, 
previous studies have shown the minimal cargo-delivery domain of PMT-N to 
consist of amino acids 1-505 [3], and mutations in a predicted helix-loop-helix 
region of PMT-N blocked pH-dependent entry into the cytoplasm that suggests 
this region is important for translocation [2]. PMT-N mediates uptake of 
exogenous proteins, including GFP [19], and delivery of diphtheria toxin catalytic 
domain [3]. Some insights have been gained into the molecular events involved 
in PMT intracellular trafficking [19]. Yet, a thorough knowledge of the role that 
each discrete C-terminal cargo subdomain of PMT plays in efficient cytosolic 
delivery is absent; in particular, it is not clear which complete or partial 
subdomains are actually delivered, or whether the delivered subdomains are 
cleaved after cytosolic delivery.  
In this chapter, I provide evidence to address the first major question of 
this thesis: During translocation of PMT from late endosomes into the cytosol of 
host cells, does the N-terminus of PMT deliver its C-terminal cargo as an intact 
moiety or as separate functional subdomains? I demonstrate that PMT delivers 
its native cargo as an intact single unit of C1-C2-C3, including its MLD, from late 
endosomes. I show that truncations of PMT (comprising residues 1-1104 or 1-
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1262) deliver the corresponding truncated cargo fragments as intact polypeptides 
without further cleavage. Furthermore, in collaboration with Elizabeth E. 
Haywood, I show that C1-C2 as a unit is important for cytosolic delivery of C3 by 
PMT-N and I further refine the minimal C3 subdomain required for intracellular 
signaling activity as amino acids 1105-1278. The data presented here lends 
insight into the functional organization of single-polypeptide A-B toxins in terms of 
the innate contribution of the cargo in the cytosolic delivery process. This 
information is important to synthetic biology for the development of protein toxin-
based platforms, such as Bacterial Toxin-Inspired Drug Delivery (BTIDD) [9], for 
cytosolic delivery of novel therapeutics. 
 
2.2 Materials and Methods 
Plasmid constructs  
The gene for PMT N-terminal fragment (1-568, denoted as PMT-N) were 
cloned into the pET21b expression vector (Novagen), and the corresponding 
recombinant proteins were expressed in E. coli BL21 cells (Novagen) under 
control of an IPTG-inducible promoter. HA tags were introduced and truncations 
generated by several rounds of primer extension and were then incorporated into 
pTHC-toxA (Invitrogen) or pGEP-1 expressions vectors by fragment exchange. 
The genes for full-length PMT and PMT truncations, C-terminally HA-tagged 
PMT and C-terminally HA-tagged PMT truncations proteins were cloned into the 
pTrcHisC (Invitrogen) or pGEP-1 expression vectors.  
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Expression, purification, and quantification of PMT, HA-tagged PMT 
variants, and HA-tagged MLD and DMLD variants  
All recombinant proteins were expressed in E. coli TOP10 or BL21 cells 
(Invitrogen) under control of an IPTG-inducible promoter, essentially as 
described previously [19, 9]. Briefly, the recombinant proteins were purified from 
cellular extracts by Ni2+-chelation affinity chromatography using a Ni2+-NTA-
agarose column (Qiagen), followed by anion exchange chromatography using a 
HiTrapQ column (Amersham). The His6-tag was removed for recombinant PMT 
using Thrombin Cleavage Capture Kit (Novagen), and the protein was further 
purified by anion exchange chromatography using a HiTrapQ column. The toxin-
containing fractions were desalted by PD-10 column (Amersham) using 1x 
phosphate-buffered saline (PBS, 10 mM phosphate, 137 mM NaCl, 2.7 mM KCl, 
pH 7.4) containing 10% glycerol. Protein concentrations of the resulting purified 
proteins were determined by quantitative digital image analysis using NIH 
ImageJ software of SDS-PAGE gels stained with Pierce GelCode Blue and using 
bovine serum albumin (BSA) as the protein standard. The toxin samples were 
flash-frozen and stored at −80°C until used. Biological activity of purified full-
length proteins, PMT (no His) and PMT-HA, was confirmed as previously 
described [9, 21], with an EC50 value of 0.6 nM.  
Cell culture 
HEK293-T cells (ATCC # CRL-11268) were cultured in DMEM (Gibco-
Invitrogen, Grand Island, NY, USA), supplemented with 0.37% sodium 
bicarbonate, 100 U/mL penicillin-streptomycin (ThermoFisher Scientific) and 10% 
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fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA, USA) or 10% 
BGS (HyClone). The cells were maintained in DMEM with 5% or 10% FBS or 
BGS and stepped down to 2% FBS or BGS at the time of transfection before 
experiments were performed. Swiss 3T3 cells (ATCC# CCL-92) were cultured at 
37ºC and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO), 
supplemented with 10% heat-inactivated bovine growth serum (BGS, HyClone), 
pH 7.4, and containing 100 units/mL penicillin G and 100 µg/mL streptomycin. 
For transient transfection experiments, cells were plated onto 6-well plates at 70-
80% confluence 24 hrs prior to transfection. Transfection was performed using 
TransIT-LT1 reagent (Mirus), according to the manufacturer’s protocol. In short, 
250 μL of serum-free Opti-MEM was mixed with 7.5 μL TransIT-LT1 Reagent by 
pipetting gently and 2.5 μg plasmid DNA was added to the mixture and incubated 
at room temperature for 15-30 min. During the incubation, the medium from each 
well was replaced with fresh DMEM supplemented with 10% BGS, and the 
TransIT-LT1 Reagent-DNA complex was added to the cells and incubation 
continued at 37°C and 5% CO2. Medium was replaced after 24 hrs. Two days 
later, transfection efficiency was determined by visualization using fluorescence 
microscopy (Olympus IX-70 inverted fluorescence microscope equipped with an 
Olympus DP70 digital camera or Zeiss Axiovert 200M inverted fluorescence 
microscope). 
Toxin treatment of cells 
Swiss 3T3 or HEK-293T cells, cultured as above, were plated onto 6-well 
plates at a density of 0.3 x 106 cells/well or onto 100-mm culture dishes at a 
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density of 4 x 106 per plate and incubated at 37°C and 5% CO2 for one to two 
days prior to toxin treatment. For experiments involving C-terminal HA-tagged 
PMT variants (full-length or truncations), after one to two days post plating, 
medium was replaced with fresh DMEM supplemented with 10% BGS containing 
toxin at the indicated concentrations and treatment times incubated at 37°C. After 
toxin treatment, cells were washed 3 times with warm 1x PBS (2 min each), 
replaced with fresh DMEM supplemented with 10% BGS without toxin, incubated 
at 37°C for 60 min. This 3X wash and toxin-free media replacement step was 
subsequently repeated two more times. Cells were washed three more times with 
warm 1x PBS (2 min each), and then washed twice with cold 1x PBS before 
harvesting the cells. 
For all types of treatments, the cells were collected and analyzed using 
subcellular fractionation method (see below). All the experiments shown were 
repeated independently at least three times. 
Subcellular fractionation 
For subcellular fractionation using high-speed ultracentrifugation, Swiss 
3T3 or HEK-293-T cells were cultured, plated, and treated as described above. 
The cells were collected in cold 1x PBS, then centrifuged for 5 min at 4°C and 
3,000 x g to pellet the cells. Cell pellets were washed with cold 1x PBS and then 
re-centrifuged for 5 min at 3,000 x g at 4°C. The cell pellets were resuspended in 
0.5 mL homogenization buffer (250 mM sucrose, 0.5 mM EDTA containing 1x 
protease inhibitor cocktail and homogenized at 4°C by 30 passages through a 
263/8-gauge needle fitted using a 1-mL syringe. The homogenate was 
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fractionated by centrifugation for 10 min at 800 x g at 4°C to separate nuclear 
pellet, comprised of nuclei and cell debris, and post-nuclear-supernatant 
(Intracellular fraction), comprised of organelles and cytosolic components. For 
further subcellular fractionation, the intracellular fraction was centrifuged at 
100,000 x g for 1 hour at 4oC using a TH-660 rotor to enrich for microsomal 
pellet, comprised of vesicles, which were solubilized in homogenization buffer 
(vesicle fraction). The cytosolic proteins remained in the supernatant (cytosolic 
fraction). 
For subcellular fractionation using bench top centrifugations, Swiss 3T3 or 
293-T cells were cultured, plated, and treated as described above. The washed 
cell pellets were resuspended in 250 µL of homogenization buffer (250 mM 
sucrose, 0.5 mM EDTA, containing 1x PI) and homogenized at 4°C via 10 
plunges in a 2-mL douncer. The homogenate was centrifuged for 5 min at 750 x 
g at 4°C to separate nuclear pellet, comprised of nuclei and cell debris, and post-
nuclear-supernatant (intracellular fraction), comprised of organelles and cytosolic 
components. The intracellular fraction was further centrifuged at 30,000 x g for 1 
hour at 4oC using a Hettich Mikro 22R centrifuge to enrich for microsomal pellet 
containing vesicles. The vesicle pellet was solubilized in homogenization buffer 
(vesicle fraction). The resulting supernatant was further centrifuged at 30,000 x g 
for 1 hour at 4oC using a Hettich Mikro 22R centrifuge to remove any residual 
debris. The supernatant contained cytosolic proteins (cytosolic fraction). All the 
experiments shown were repeated independently at least three times. 
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SDS-PAGE and immunoblot analysis 
Protein samples from above were separated by 10% or 12% SDS-PAGE, 
transferred to polyvinyl difluoride or nitrocellulose membranes (Pall Life 
Sciences) and analyzed by immunoblot, using standard procedures with the 
following primary antibodies against the indicated proteins: rabbit polyclonal anti-
β-Tubulin (ab6046, Abcam), mouse monoclonal anti-Rab5 (D11) (sc46692, 
Santa Cruz Biotechnology), or mouse monoclonal anti-HA (26183, Thermo 
Scientific). Specific protein bands were visualized by ECL Plus System (GE Life 
Sciences) using appropriate HRP-conjugated secondary antibodies: goat anti-
mouse or goat anti-rabbit. Blots were scanned using an HP Scanjet G4050 
scanner, and images were quantified using NIH Image J.  
SRE-luciferase reporter assay and data analysis 
SRE-luciferase reporter assays were performed and analyzed, as 
previously described [9]. Briefly, HEK-293T cells plated on 24-well plates at a 
density of 7.5 x 104 cells/well were transfected with reporter plasmids. After 7 
hours, cells were treated with the indicated toxin at the indicated doses and 
incubated for 18 hours prior to assay. To calculate fold activation, the firefly 
reporter relative luminescence units (RLUs) were divided by the control Renilla 
RLUs and then normalized to the corresponding value for untreated samples. 
The relative PMT activation was determined compared to the maximum 
activation observed for PMT (no His) or PMT, as indicated. Data points shown 
are the means, plus or minus the standard deviation (SD). To calculate the dose 
response curves, the relative PMT activation for each data point was compiled 
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and analyzed with the Solver function in Microsoft Excel to generate a best fit, 
four-parameter logistic (4PL) equation:  
 
where A = minimum asymptote, B = slope, C= point of inflection or the EC50 
value, and D = maximum asymptote. The best-fit curve was optimized for the 
least sum of the squared difference between observed and expected 4PL values. 
 
2.3 Results  
Cytosolic cargo delivery of C-terminal PMT fragments by PMT-N 
 I first asked whether the entire, intact C-terminus of PMT (comprised of 
C1-C2-C3) or portions thereof are delivered into the cytosol of host cells. For 
sensitive immunoblot detection, HA-tagged protein fusions at the C-terminus or 
N-terminus of PMT were used to examine toxin localization within cells by 
subcellular fractionation and immunoblot analysis. Labeling the N-terminus of 
PMT with an HA-tag was found to interfere with cell binding (data not shown), 
and so was not further explored. While designing C-terminal HA-tagged protein 
fusions, we considered that lysine and arginine residues present near or within 
loops between residues 1260-1285 (K1263, K1278, R1280, R1283) might be 
subject to trypsin-like proteases, such that the HA-tags could be lost upon 
proteolytic cleavage, thus rendering the toxin undetectable via immunoblot. 
Whether this positively charged region was critical for stability or cytosolic 
delivery of the C-terminus of PMT was also considered. Finally, there was 
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concern that PMT-induced cell rounding and detachment might diminish cellular 
uptake and accumulation of HA-tagged proteins. To address these issues, a 
series of recombinant toxin fusions with HA-tags directly at the C-terminus were 
generated and purified (Figure 2.2A and 2.2B): after residue 1285 for full-length 
PMT (PMT-HA) and a catalytically inactive mutant (PMTC1165S-HA); and for 
truncations after residues 1277 (PMT-1277-HA) and 1262 (PMT-1262-HA).  
To determine which portion of the C-terminus of PMT is delivered into the 
cytosol, toxin-treated cells were subjected to subcellular fractionation to separate 
contents first into two fractions: one comprised of nuclei, large organelles, and 
cellular debris and the other (denoted as the intracellular fraction) comprised of 
small membrane vesicles and soluble cytosolic components. The intracellular 
fraction was further separated into membrane vesicles (vesicle fraction) and 
soluble cytosolic components (cytosolic fraction) (a representative separation 
technique example is shown in Figure 2.2C).  
Swiss 3T3 cells were first treated with PMT-1262-HA, PMT-1277-HA, 
PMT-HA, and PMTC1165S-HA. The cytosolic fractions were resolved via SDS-
PAGE gel and then visualized using immunoblot analysis. As expected, while 
corresponding full-length HA-tagged toxin could be detected in the respective 
vesicle fraction, none was observed in the cytosol (a representative example 
profile for PMT-1262-HA is shown in Figure 2.2D). The cytosolic fractions for 
each of the fusion proteins revealed protein bands close in size to the expected 
C-terminal fragment of ~80 kDa for intact cargo of the respective HA-tagged toxin 
(Figure 2.2E), although the corresponding band for PMT-1277-HA was weaker 
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than the others. These results indicate that the entire C-terminal cargo is 
delivered intact into the cytosol. 
I also asked whether the entire, intact C1-C2-C3 module, as depicted in 
the crystal structure (Figure 2.1), was required for delivery of the C-terminal 
cargo. To address this, I made a truncation of PMT where the C3 subdomain was 
deleted (PMT-C1-C2-HA) (Figure 2.2A and 2.2B). A truncation where C2-C3 was 
deleted (PMT-C1-HA) was not stably expressed (data not shown). The cytosolic 
fraction of cells treated with PMT-C1-C2-HA showed a protein band near the 
expected C-terminal fragment size of ~60 kDa for intact cargo of PMT-C1-C2-HA 
(Figure 2.2E), indicating that C1-C2 alone could be delivered intact.  
Delivered PMT cargo does not undergo further proteolytic processing 
between C-terminal subdomains 
 Next, I asked if C-terminal fragments of PMT cargo undergo any further 
proteolytic cleavage between subdomains. To address this question, I generated 
full-length PMT with one or two HA-tags inserted in between subdomains C2 and 
C3 near potential trypsin-like protease cleavage sites (PMT-C1-C2-HA-C3 and 
PMT-C1-C2-HA-HA-C3) (Figure 2.2A and 2.2B). The intracellular fractions of 
HEK-293T cells, treated with PMT-C1-C2-HA-C3, PMT-C1-C2-HA-HA-C3, PMT-
1262-HA, or PMT-C1-C2-HA, were resolved via SDS-PAGE then visualized 
using immunoblot analysis. No additional fragments of smaller size than the 
expected cargo were detectable for any of the HA-tagged toxins in the 
intracellular fractions (Figure 2.2F).  
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Delivered PMT C-terminal cargo includes the MLD  
Though I confirmed that the C-terminal cargos of PMT-N were delivered to 
the cytosol intact, and it appeared that the delivered cargo was not cleaved 
between subdomains C1 and C2 or C2 and C3, I noticed that the observed 
protein bands were near, but not exactly where we expected them to appear on 
the immunoblots. Fragment bands consistently migrated lower than expected, 
suggesting a smaller size. For instance, the PMT-C1-C2-HA, PMT-1262-HA, 
PMT-1277-HA, and PMT-HA fragments were expected to appear at 61, 79, 80, 
and 81 kDa, respectively, but consistently migrated lower in each case (Figure 
2.2E). This size discrepancy led us to hypothesize that part of the N-terminus of 
the expected fragment was not being delivered into the cytosol or was cleaved 
off once in the cytosol. I speculated that loss of the MLD from the C1 subdomain 
could account for the observed size discrepancy. For example, PMT-C1-C2-HA 
would yield an expected fragment C1(ΔMLD)-C2-HA at ~51 kDa and PMT-1262-
HA an expected fragment C1(ΔMLD)-C2-C3(Δ1263-1285) at ~70 kDa, which 
were where we observed the bands on immunoblots. To address whether the 
MLD was being lost during or after delivery, we generated and purified 
recombinant HA-tagged C1-C2 and C1-C2-C3(Δ1263-1285) truncated proteins 
(Figure 2.3A and 3B), where the MLD was either removed or left in place 
(denoted as ΔMLD_C1-C2-HA, MLD_C1-C2-HA, ΔMLD_1262-HA, and 
MLD_1262-HA). We chose to examine the delivered cargos from treatment with 
PMT-C1-C2-HA and PMT-1262-HA because the smaller cargos would provide 
better size resolution on immunoblots. Swiss 3T3 cells treated with PMT-C1-C2-
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HA and PMT-1262-HA were subjected to subcellular fractionation, and the 
resulting cytosolic fractions were resolved and analyzed alongside of purified 
recombinant proteins ΔMLD_C1-C2-HA, MLD_C1-C2-HA, ΔMLD_1262-HA, and 
MLD_1262-HA proteins (Figure 2.3C). Delivered cytosolic PMT-1262-HA and 
PMT-C1-C2-HA cargo fragments migrated on the gel approximately the same 
distance as the corresponding purified MLD_C1-C2-HA and MLD_1262-HA 
proteins, where the difference between observed and expected migration is 
attributed to the presence of the 1.5-kDa N-terminal His6-tag and linker on the 
recombinant MLD_C1-C2-HA and MLD_1262-HA proteins. These results 
indicate that cargo delivered by PMT-N into the cytosol is intact and includes the 
MLD. 
Cytosolic delivery of C-terminal cargos by PMT-N is time and dose 
dependent  
To further confirm that C-terminal cargo is delivered into the cytosol by 
PMT-N by a dose- and time-dependent process, we treated Swiss-3T3 cells with 
PMT-C1-C2-HA or PMT-1262-HA at varying doses or for varying time points 
before subjecting to subcellular fractionation, separation of proteins by SDS-
PAGE, and immunoblot analysis. After 4-hour treatment at the highest dose 
tested (5 µM), I was able to detect a prominent protein band in the cytosolic 
fraction corresponding to the expected HA-tagged protein fragment of each 
respective protein, while the full-length protein was confined to the vesicle 
fraction (Figure 2.4A). Cargo delivery was both dose-dependent (Figure 2.4B) 
and time-dependent (Figure 2.4C). Taken together, these results show that PMT-
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N delivers C-terminal cargos into the cytosol of host cells through a time- and 
dose-dependent mechanism. 
Cytosolic delivery of C-terminal cargos is inhibited by ammonium chloride  
To confirm that the delivered C-terminal PMT HA-tagged cargo fragments 
were being delivered to the cytosol from acidified endosomes, we tested whether 
ammonium chloride, a known intracellular acidification inhibitor of endosomes, 
would inhibit cytosolic delivery of cargo. Swiss 3T3 cells were pretreated for 30 
minutes with increasing doses of ammonium chloride, followed by treatment with 
PMT-C1-C2-HA. After subcellular fractionation, cytosolic fractions were resolved 
by SDS-PAGE and subjected to immunoblot analysis. As expected, pretreatment 
with increasing dosages of ammonium chloride decreased the amount of C1-C2-
HA fragment detected in the cytosolic fractions (Figure 2.4D), indicating that 
inhibition of endosomal acidification prevents cytosolic delivery of cargo by PMT-
N and that translocation occurs from late endosomes.  
C-terminal truncations of PMT further refine the minimal C3 catalytic 
subdomain required for intracellular activity  
Since the HA-tags were not lost from full-length PMT (PMT-HA) and the 
truncations within the C3 domain (PMT-1262-HA, PMT-1277-HA) did not prevent 
the ability of PMT-N to deliver the respective C-terminal truncated cargos, we 
were interested in further refining the core region within the C3 domain required 
for intracellular activity, as evidenced by activation of a previously described 
SRE-luciferase reporter assay [1, 9]. We generated and purified a series of 
recombinant His6-tagged full-length PMT and recombinant PMT truncations 
 43 
 
without HA-tags, denoted as PMT, PMT-1262, PMT-1278, PMT-1280, PMT-1283 
(Figure 2.5A and 2.5B).  
To address whether the His6-tag might interfere with enzyme activity of the 
toxin, the His6-tag from PMT was also removed via thrombin cleavage, denoted 
as PMT (no His). While the presence of the N-terminal His6-tag had a detectable 
effect on the SRE-luciferase activity of PMT versus PMT (no His) (Figure 2.5C), 
we concluded that this minor difference would not interfere significantly with 
determination of relative activities among the recombinant proteins. PMT-1280 
and PMT-1283 showed wildtype-like SRE-luciferase activity, while PMT-1278 
showed approximately 1,000-fold less activity, but was able to reach maximal 
signaling activity in the range of concentrations tested (Figure 2.5D). PMT-1262 
showed no detectable SRE-luciferase activity in the range tested (Figure 2.5D). 
Previously, we defined the minimal C3 subdomain necessary for intracellular 
activity of PMT as residues 1105-1285 [1]. We now further refine the minimal 
core C3 subdomain necessary for intracellular signaling activity as residues 
1105-1278. 
Role of C1-C2 in cytosolic delivery of C3 by PMT-N 
Since PMT-N delivers intact native cargo and truncations thereof, such as 
C1-C2, and even an exogenous GFP cargo [7], we asked if PMT-N could deliver 
the C3 subdomain alone. To address this question, I generated an HA-tagged 
deletion mutant that has C1-C2 removed, denoted PMT-C3-HA (Figure 2.6A and 
2.6B). Swiss-3T3 cells were treated with 5 µM PMT-C3-HA or PMTC1165S-HA for 
18 hours and subsequently subjected cells to subcellular fractionation, followed 
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by SDS-PAGE and immunoblot analysis. The expected fragment corresponding 
to C3-HA cargo alone did not appear in the cytosolic fraction of cells treated with 
PMT-C3-HA. However, as expected, a fragment corresponding to the intact C1-
C2-C3C1165S-HA cargo, but no smaller C3-HA-containing fragments, was 
observed in the cytosolic fractions of cells treated with PMTC1165S-HA (Figure 
2.6C).  
I speculated that C3 may be delivered, but at levels that were not 
detectable by immunoblot analysis. To test this possibility, I explored the more 
sensitive SRE-luciferase assay for detecting whether C3 was delivered into the 
cytosol by assaying downstream intracellular activity. For this, I generated a 
recombinant PMT-C3 without an HA-tag (Figure 2.6A and 2.6D) and test for 
SRE-luciferase reporter activity. Intracellular signaling activity was detected only 
for full-length recombinant PMT, but not for PMT-C3 (Figure 2.6E). I also 
considered the possibility that recombinant proteins without HA-tags, where only 
C1 or C2 subdomains were deleted (Figure 2.6A and 2.6D) might restore SRE-
luciferase reporter activity; however, none of the resulting internal deletion 
mutants displayed detectable intracellular activity above controls (Figure 2.6E). In 
total, these results demonstrate that native cargo is delivered by PMT-N as an 
intact unit comprised of C1-C2-C3 and support a model whereby C1-C2 is 
important for delivery of C3 by PMT-N. 
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2.4 Discussion 
PMT belongs to a growing superfamily of single-chain bacterial A-B toxins 
that utilize discrete modular domains to carry out specific functions of the 
intoxication process. A number of advancements have been made in elucidating 
the modular nature and functional organization of the PMT-related dermonecrotic 
toxin family, which includes the cytotoxic necrotizing factors (CNF) from E. coli 
and Yersinia psuedotuberculosis and the dermonecrotic toxin (DNT) from 
Bordetella sp. [reviewed in 11, 23, 24]. The available crystal structures of the C-
terminal domains of PMT [13] and CNF1 [5] have helped define the subdomains 
that comprise the cargo modules responsible for intracellular toxic activity. In 
both instances, the far C-terminal subdomain corresponding to C3 in PMT 
harbors the Gα-protein Gln-deamidase activity [1, 5, 8, 13, 20]. However, no 
corresponding structure of the N-terminus of this family of toxins is available, and 
so the mechanism by which the N-terminal modules mediate delivery of the 
cognate activity cargo into the cytosol of host cells is not fully understood. For 
instance, it was not known whether the three C-terminal C1-C2-C3 subdomains 
of PMT are delivered into the cytosol as an intact unit as C1-C2-C3 or undergo 
proteolytic processing before or after translocation. It was also not known 
whether the nature of the cargo itself participates in the delivery process or 
contributes to the efficiency of its delivery. I also asked if the N-terminal cargo-
delivery module of PMT (PMT-N) could deliver exogenous non-enzymatic cargo 
into the cytosol of host cells. 
 46 
 
In this chapter, in order to gain further insight into the cargo-delivery 
process, I first sought to demonstrate the cellular uptake and localization of the 
cargo subdomains of PMT. Through the use of subcellular fractionation of cells 
treated with HA-tagged recombinant toxin fusion proteins, followed by SDS-
PAGE and immunoblot analysis, I clearly demonstrated that the three C-terminal 
subdomains are delivered by PMT-N into the cytosol of host cells as an intact 
C1-C2-C3 unit, and no individual subdomains or further proteolytically cleaved 
products were detected in the cytosol. Results also showed that PMT-N delivers 
truncations of the C-terminus as fragments corresponding to intact cargo units, 
as evidenced by the delivery of the corresponding cargo of PMT-C1-C2-HA, 
PMT-1262-HA, and PMT-1277-HA. I further demonstrated the dose- and time-
dependent cytosolic delivery of C1-C2-HA and C1-C2-C3. In agreement with 
previous studies demonstrating the dependence of PMT intracellular activity on 
acidification of late endosomes [19], cytosolic delivery of C1-C2-HA from 
endocytic vesicles was prevented by ammonium chloride. In addition, the 
observed cytosolic fragments possess the MLD at the N-terminus of the 
delivered cargo. Moreover, through the use of SRE-luciferase reporter assay, it 
was possible to conclude that the core C3 subdomain required for intracellular 
activity is comprised of residues 1105-1278, though shorter truncations at 
residues 1104 (PMT-C1-C2-HA) and 1262 (PMT-1262 and PMT-1262-HA) were 
stably expressed, purified, and delivered into the cytosol.  
Since it appeared that truncations that affected or removed the C3 
subdomain did not hamper their respective delivery and that PMT-N could deliver 
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GFP from late endosomes in the cytosol [7], each as intact units, I consequently 
asked whether C3 could be delivered by PMT-N without C1, C2 or C1-C2. 
However, whether using subcellular fractionation and SDS-PAGE-immunoblot 
analysis for detection of C3 cytosolic delivery or the SRE-luciferase reporter 
assay for intracellular activity, we saw no evidence of C3 delivery by PMT-N for 
any of the C1, C2, or C1-C2 deletions. It was thus concluded that in the case of 
the native toxin cargo, the presence of C1-C2 is important for the delivery of the 
catalytic subdomain C3. 
Understanding the molecular organization and functional modularity of A-B 
toxins enables their manipulation for potential therapeutic applications as delivery 
vehicles for various therapeutic cargos. Work from our laboratory has begun to 
investigate the considerations involved in the assembly of functional modules 
and the limitations of swapping domains and cargos of bacterial toxins. Recent 
work from our laboratory indicates that the efficiency of the delivery vehicle to 
transfer cargo into the cytosol depends in part upon the intrinsic nature of the 
cargo itself, in such a way that perhaps the cargo plays an important role in 
concert with the delivery vehicle to ensure effective translocation [9]. As 
evidenced by the importance of C1-C2 for delivery of C3, these results allow us 
to draw a similar deduction that the cargo partly contributes to its own delivery. 
The observation that PMT-C1-HA was not stably expressed, but PMT-C1-C2-HA 
was expressed and effectively delivered the C1-C2-HA cargo and other C-
terminal peptides (C3 and truncations thereof), suggests that the use of PMT-C1-
C2 might be an alternative delivery vehicle for some cargos.  
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Based on the findings from this study and prior work from our laboratory 
and that other groups, a model for PMT intoxication and cytosolic delivery of 
cargo is proposed here (Figure 2.7): Upon cell binding the cell-surface receptors, 
full-length PMT is taken up by endocytosis and is trafficked from early to late 
endosomes. Upon the lowering of the endosomal pH, instead of being trafficked 
to the lysosomal degradative pathway, acidification of PMT-N triggers 
conformational changes and membrane interactions that facilitate the 
translocation of cargo. During this process, C1-C2 first translocates across the 
endocytic membrane and subsequently pulls C3 through into the cytosol. The 
translocated intact C1-C2-C3 is cleaved near the MLD of C1 and the MLD helps 
to localize the intact C1-C2-C3 at the plasma membrane, bringing the catalytic 
subdomain C3 in proximity to its target Gα subunit.  
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2.6 Figures 
 
 
Figure 2.1. Crystal Structure of C-terminal catalytic domain of PMT. Shown 
is the crystal structure of PMT C-terminus (amino acid residues 575-1285) 
rendered from PDB 2EBH in PyMOL. C1 subdomain is depicted in red (residues 
575-668) + blue (residues 669-719), where red highlights the region containing 
the membrane localization domain (MLD). C2 subdomain (amino acid residues 
721-1104) is depicted in green. C3 catalytic subdomain is depicted in magenta 
(residues 1105-1262) + black (residues 1263-1277) + orange (residues 1278-
1285). 
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Figure 2.2. 
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Figure 2.2. (continued) 
 
C 
                                      
 
 
 
 
 
 
D 
                      
 
 
 
 
 
Anti-Rab5
Anti-Tubulin
Ve
sic
les
Cy
tos
olic
Int
rac
ellu
lar
Int
rac
ellu
lar
 0.
5 µ
M
Ve
sic
les
 0.
5 µ
M
Cy
tos
olic
 0.
5 µ
M
Full Length
Fragment
150
75
50
Anti-Tubulin
Anti-Rab5
**
Int
rac
ellu
lar
 Co
ntr
ol
Anti-HA for PMT-1262-HA
 53 
 
 
Figure 2.2. (continued) 
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Figure 2.2. (continued) 
 
Figure 2.2. Cytosolic cargo delivery of C-terminal catalytic domain 
fragments by PMT-N. (A) Schematic diagram of recombinant His6-tagged PMT-
HA toxin and variants thereof constructed for this study. Black bars indicate 
where His6-tags were located. Striped boxes indicate where HA-tags were 
located. For PMT-C1-C2-HA-C3 and PMT-C1-C2-HA-HA-C3, HA-tags we 
inserted at positions 1105 or both 1105 and 1118. (B) Representative Coomassie 
blue-stained protein gels (left) and corresponding immunoblots (right) of the 
recombinant PMT-HA toxin variants used in this study, as indicated in the figure. 
(C) Representative immunoblot of subcellular fractions, demonstrating the 
benchtop centrifugation technique for subcellular fractionation, as outlined in the 
Materials and Methods section. Anti-b-tubulin antibody was used as a cytosolic 
protein marker, and anti-Rab5 antibody was used as an endosomal vesicle 
marker for the same immunoblot membrane. (D) Representative immunoblot 
profile obtained from subcellular fractionation of Swiss-3T3 cells treated with 500 
nM PMT-1262-HA for 18 hours. As subcellular fractionation controls, samples of 
the same corresponding treatment fractions were used to blot for the cytosolic 
marker b-tubulin and the endosomal vesicle marker Rab5. (E) Shown is a 
representative immunoblot blot of cytosolic fractions, showing the subcellular 
localization of HA-tagged protein fragments in Swiss-3T3 cells treated with the 
indicated PMT-HA variants at 500 nM for 18 hours. Top and middle panels are 5-
minute and 15-minute exposures, respectively, of the radiography film to the 
immunoblot nitrocellulose membrane. Bottom panel is the same immunoblot  
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Figure 2.2. (continued) 
 
membrane blotted for the cytosol marker b-tubulin as a loading control. (F) 
Shown is a representative immunoblot blot of intracellular fractions, showing HA-
tagged protein fragments present in HEK-293T cells treated with the indicated 
PMT-HA variants at 250 nM for 4 hours. Top and bottom panels are 5-minute 
and 2-minute exposures, respectively, of radiography film to the immunoblot 
nitrocellulose membrane. Controls are mock treated cells with no toxin in the 
DMEM medium. Double asterisks (**) indicate anti-HA antibody cross-reactive 
material. Arrows indicate non-cleaved full-length toxin. Arrowheads indicate 
expected cleaved HA-tagged protein fragments. Numbers directly to the left of 
gels and immunoblots indicate molecular mass (kDa) based on standard protein 
markers (M). For each gel or blot of fractions from cell treatments, lanes were 
loaded with equal volume of sample. 
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Figure 2.3. 
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Figure 2.3. (continued) 
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Figure 2.3. The membrane localization domain is included in the delivered 
cytosolic cargo. (A) Schematic diagram of the His6-tagged MLD-HA and ΔMLD-
HA protein variants used in this study. Black bars indicate where His6-tags were 
located. Striped boxes indicate where HA-tags were located. (B) Representative 
Coomassie blue-stained protein gels (left) and immunoblots (right) for the 
indicated MLD proteins used in this study. Asterisks (*) indicate impurities. (C) 
Representative immunoblot of cytosolic fractions, showing cleaved toxin 
fragments from cells treated with the indicated PMT-HA variants. Cytosolic 
fractions were resolved alongside the indicated purified MLD and ΔMLD proteins. 
Double asterisks (**) indicate anti-HA antibody cross-reactive material. Numbers 
directly to the left of gels and immunoblots indicate molecular mass (kDa) based 
on standard protein markers (M). For each gel or blot of fractions from cell 
treatments, lanes were loaded with equal volume of sample. 
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Figure 2.4. 
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Figure 2.4. (continued) 
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Figure 2.4. Time, dose, and endosome acidification dependence of cytosolic 
delivery of cargo by PMT-HA variants. (A) Representative immunoblot of 
subcellular fractionation profile for Swiss 3T3 cells treated with 5 µM PMT-C1-C2-
HA (top three panels) or PMT-1262-HA (bottom three panels) for 4 hours. Samples 
of the same corresponding treatment were used to blot for the cytosol marker b-
tubulin and the endosomal vesicle marker Rab5. (B) Representative immunoblot 
of cytosolic fractions for dose response of Swiss 3T3 cells treated with PMT-C1- 
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Figure 2.4. (continued) 
 
C2-HA or PMT-1262-HA at the indicated dosages for 4 hours. Samples of the 
same corresponding treatment were used to blot for the cytosol marker b-tubulin. 
(C) Representative immunoblot of cytosolic fractions for time course of Swiss 3T3 
cells treated with 5 µM PMT-C1-C2-HA or PMT-1262-HA at the indicated times. 
Samples of the same corresponding treatment were used to blot for the cytosol 
marker b-tubulin. (D) Representative immunoblot of cytosolic fractions for 
response of Swiss 3T3 cells pretreated with the indicated dosages of ammonium 
chloride for 60 minutes, followed by treatment with 1 µM PMT-C1-C2-HA for 6 
hours. The cytosolic marker b-tubulin was used as internal control. Plotted data 
are presented as the mean ± SD. Filled bars: relative ratio of C1-C2-HA/b-tubulin. 
N=6, except for 40-mM data points, where N=3. *P < 0.05 and **P < 0.01, C1-C2-
HA levels versus control (unpaired two-tailed Student’s t-test). Numbers directly to 
the left of gels and immunoblots indicate molecular mass (kDa) based on standard 
protein markers (M). For each gel or blot of fractions from cell treatments, lanes 
were loaded with equal volume of sample. 
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Figure 2.5. 
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Figure 2.5. (continued) 
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Figure 2.5. (continued) 
 
Figure 2.5. Refining the minimal C3 subdomain responsible for intracellular 
activity. (A) Schematic diagram of recombinant PMT with the His6-tag removed 
(no His), His6-tagged PMT, and indicated His6-tagged PMT truncations used in 
this study. Black bars indicate where His6-tags were located. (B) Representative 
Coomassie blue-stained gel of PMT (no His), His6-tagged PMT, and indicated 
His6-tagged PMT truncations used in this study. Numbers directly to the left of the 
gels indicate molecular mass (kDa) based on standard protein markers. (C) 
Effect of His6-tag on PMT intracellular activity. Dose-response curves for 
intracellular activity of HEK-293T cells transfected with SRE-luciferase gene 
reporter plasmids and then treated with the indicated proteins at the indicated 
doses and subjected to SRE-luciferase assay, as described in the methods. 
Relative PMT activation values are in comparison to untreated cells, normalized 
to the maximum activation of PMT (no His), as indicated and as determined by 
the 4PL equation for each experiment. (D) Dose-response curves for PMT 
intracellular activity of C-terminal truncations of PMT. Shown are the dose 
response curves for intracellular activity of the indicated proteins, performed 
similar to that above in (C). Results shown in (C) and (D) are from 3 independent 
experiments, where each data point was performed in triplicate. 
 
   
 
 
 
 
 
 
 64 
 
 
Figure 2.6. 
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Figure 2.6. (continued) 
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Figure 2.6. (continued) 
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Figure 2.6. Role of C1-C2 in cytosolic delivery of C3 by PMT-N. (A) 
Schematic diagram of HA-tagged and His6-tagged C-terminal deletion mutants of 
PMT used in this study. Black bars indicate where His6-tags were located. 
Striped bars indicate where HA-tags were located. (B) Shown is a representative 
Coomassie blue-stained gel (left) and immunoblot (right) of His6-tagged PMT-C3-
HA used in this study. (C) Shown is a representative immunoblot of cytosolic 
fractions from Swiss 3T3 cells treated for 18 hours with 5 µM PMTC1165S-HA or 5 
µM PMT-C3-HA, showing cleaved HA-tagged fragments. The same immunoblot 
membrane was blotted for the cytosolic marker β-tubulin. (D) Shown is a 
representative Coomassie blue-stained gel of the His6-tagged C-terminal deletion 
mutants of PMT used in this study. (E) Intracellular signaling activity of C-terminal  
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Figure 2.6. (continued) 
 
deletion mutants of PMT. Shown are dose-response curves for intracellular 
activity of HEK-293T cells transfected with SRE-luciferase gene reporter 
plasmids and then treated with the indicated proteins at the indicated doses and 
subjected to SRE-luciferase assay, as described in the methods. Relative PMT 
activation values are in comparison to untreated cells, normalized to the 
maximum activation of PMT, as indicated and as determined by the 4PL equation 
for each experiment. Results shown are from 3 independent experiments, where 
each data point was performed in triplicate. 
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Figure 2.7. Proposed model for PMT intoxication and cytosolic cargo 
delivery by PMT-N. 
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Chapter 3 
Interior redecorating: Selective membrane redistribution 
and depletion of Gαq-protein by Pasteurella multocida toxin 
 
3.1 Introduction 
Pasteurella multocida toxin (PMT) is the major virulence factor responsible 
for atrophic rhinitis, pasteurellosis, and dermonecrosis caused by toxigenic 
strains of P. multocida [reviewed in 48]. PMT is a 146-kDa AB toxin that acts 
intracellularly by gaining entry into host cells via binding membrane 
phospholipids and an as-yet unknown trypsin-sensitive protein partner [7]. PMT 
is subsequently endocytosed and released from the late endosomes into the 
cytosol in a pH dependent manner [6, 31, 32], where it targets heterotrimeric G-
proteins and modulates their downstream signaling pathways [reviewed in 6]. 
PMT acts on α subunits of the Gαq/11, Gα12/13, and Gαi1/2/3, but not Gαs, families 
[12, 23, 47, 50] through deamidation of a specific Gln residue in the switch II 
region of the active site of Gα subunits [26], changing Gln into Glu and converting 
the Gα-protein into a constitutively active form.  
PMT action leads to stimulation of phospholipase C β-1 (PLCβ1) signaling 
through its preferential activation of Gαq of the Gαq/11 family of G-proteins [47,50]. 
By doing so, PMT increases the intracellular cytoplasmic concentration of Ca2+ 
and activates mitogenic signaling pathways, leading to increased cellular 
proliferation and in some cell types cell differentiation [37, 47]. PMT also 
indirectly activates Rho signal transduction through its action on Gαq/11 and 
Gα12/13 [5, 25, 33, 42], leading to actin cytoskeletal rearrangements and changes 
in cellular morphology [9, 13, 25, 36, 39, 44, 50]. Thus far, the only Gα family that 
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PMT does not deamidate or activate is Gαs [3, 22, 23], the stimulatory regulator 
of adenylate cyclase (AC). Conversely, PMT inhibits AC activity through its 
activation of inhibitory AC regulators of the Gαi family [22]. PMT activation of 
these different G-protein signaling pathways, in conjunction with crosstalk among 
the downstream signaling pathways, can lead to multiple cellular outcomes 
[reviewed in 45, 46]. 
Although PMT modulates intracellular signaling pathways to dictate 
cellular fate by constitutive activation of Gα proteins, the overall activation of 
downstream signaling is not persistent and is followed by downregulation. PMT 
causes an initial strong activation of downstream calcium and mitogenic 
signaling, which is subsequently followed by an uncoupling of the signaling in the 
case of Gαq-PLCβ1 [44,47] and Gαi-AC [22]. Moreover, it has been shown that 
prolonged PMT treatment is sufficient to downregulate Gαq-mediated G-protein-
coupled inward rectifying K+ channels [8,17,20] and to block agonist-induced 
binding of GTPγS binding to Gαi protein [22].  
It is known that continuous exposure of G-protein-coupled receptors 
(GPCR), to their cognate agonist results in desensitization of the pathway due to 
a sequestration, modification or reduction in cellular levels of the receptor and/or 
the Gα subunit [11, 14, 16, 34, 35, 41, 49]. This desensitization and 
downregulation may also result from a redistribution of the Gα proteins in the 
membrane to the cytosol, or within membranes from detergent resistant 
membranes (DRMs, or lipid rafts) to more soluble membranes [10, 21, 30, 38, 
49]. Indeed, some GPCRs, G proteins, and their effectors are not only localized 
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in DRMs, but also dynamically move in and out of them during signal 
transduction [27]. In each of these cases, the downregulation of Gα signaling was 
mediated through agonist binding of the GPCR. Until now, discerning how the 
subsequent cellular downregulation of PMT-modified Gα-proteins occurs has not 
been studied.  
In this chapter, the fate of the Gαq, Gα11, and Gαs proteins in HEK-293T 
cells after PMT treatment is investigated by determining the levels of the Gα 
protein in whole cell lysates, total membranes, DRMs, and the soluble membrane 
and cytosolic fractions. Results from these experiments indicate that treatment of 
HEK-293T cells with wildtype PMT, but not catalytically inactive mutant PMT 
(C1165S), stimulates the selective downregulation of Gαq, but not Gαs or Gα11, 
through redistribution of the Gαq protein from DRMs to soluble membrane and 
cytosolic fractions with overall loss of Gαq protein from the plasma membrane.  
 
3.2 Materials and Methods  
 
Materials 
Human embryonic kidney 293-T (HEK-293T) cells were obtained from the 
American Type Culture Collection (ATCC # CRL-3216). Goat polyclonal 
antibodies against Gαs (A-16, sc-26766), mouse monoclonal antibody against β 
tubulin (D-10, sc-5274), rabbit polyclonal antibodies against Gαq/11 (C-19, cat# 
sc-392), Gβ (T-20, sc-378) and flotillin-1 (H-104, sc-25506), as well as 
horseradish peroxidase-conjugated donkey anti-goat IgG (sc-2020), goat anti-
rabbit IgG (sc-2004), and goat anti-mouse IgG (sc-2005) antibodies, were 
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purchased from Santa Cruz Biotechnology (Dallas, TX, United States). Mouse 
monoclonal anti-FLAG antibody (M2, F3165) and mammalian protease inhibitor 
cocktail was purchased from Sigma (St. Louis, MO, United States). All cell 
culture reagents were purchased from Life Technologies (Thermo Fisher 
Scientific, Grand Island, NY, United States). Restriction enzymes and other 
molecular biology reagents were obtained from Roche Biochemicals (Sigma-
Aldrich, St. Louis, MO, USA). or New England Biolabs (Ipswich, MA, United 
States).  OptiPrep was obtained from Axis-Shield PoCAS (Dundee DD2 1XA, 
Scotland, UK). SuperSignal West Pico Chemiluminescent Substrate was 
purchased from Pierce Biotechnology (Thermo Fisher Scientific, Grand Island, 
NY, United States). Bio-Rad protein assay dye reagent was purchased from Bio-
Rad Laboratories (Hercules, CA, United States). Full-length recombinant PMT 
and catalytically inactive mutant PMT C1165S were cloned, expressed, purified, 
quantified, and assayed for biological activity, as previously described [2, 31, 44]. 
Mammalian expression vectors encoding Gα proteins 
DNA encoding human Gαq, Gα11, Gαq Q209L, and Gα11 Q209L genes 
(GB ACC# U43083; UMR cDNA Resource Center: [40]) was cloned into the 
KpnI/XhoI sites of pcDNA3.1+ (Invitrogen, Thermo Fisher Scientific, Grand 
Island, NY, United States). For immunoblot detection, a FLAG-tag flanked at 
each end by a 6-amino acid residue linker sequence (SGGGGS) was introduced 
between residues 121 and 122 of Gαq and Gα11 through several rounds of 
primer extension. 
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Transient Transfection  
HEK-293T cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with L-glutamine and 10% (v/v) bovine growth serum at 
37 °C and 5% CO2. Cells grown to 60%–80% confluence (~4 × 106 per 100-mm 
dish) were transiently transfected for 24 h with mammalian expression vectors: 
pcDNA3.1 (empty vector), pcDNA3.1/Gαq, pcDNA3.1/Gα11, pcDNA3.1/Gαq 
Q209E, pcDNA3.1/Gα11 Q209E, pcDNA3.1/Gαq Q209L, or pcDNA3.1/Gα11 
Q209L, using LipofectAMINE 2000 reagent (Invitrogen), according to the 
manufacturer’s instructions, or using the CalPhos Mammalian Transfection 
protocol (Clonetech Laboratories, Takara Bio USA, Mountain View, CA, United 
States). 
Cellular Fractionation  
HEK-293T cells, transfected as described above, were treated with or 
without the indicated amounts of PMT for the indicated times, washed with 1x 
cold phosphate buffered saline, scraped and transferred into a microcentrifuge 
tube (Dot Scientific Inc., Burton, MI, United States), then lysed by 10 passages 
through a 27-gauge needle in 0.5 mL of an ice-cold lysis buffer A (50 mM Tris-
HCl, pH 8.0, 2.5 mM MgCl2, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 
mM benzamidine, 1 mM dithiothreitol, and 10% glycerol) to generate whole cell 
lysates. Cellular fractionation was performed essentially as described previously 
[19]. In brief, nuclei were pelleted by centrifugation at 4°C and 750× g for 5 min, 
and the post-nuclear supernatant was fractionated into membrane pellets and 
supernatants by centrifugation at 4°C and 18,000× g for 30 min. The membrane 
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pellets were resuspended in 0.5 mL of lysis buffer A. Membrane proteins were 
quantified using the Bio-Rad protein assay. Samples containing 10 µg of total 
membrane proteins were resolved by SDS-PAGE and analyzed by 
immunoblotting, as described below.  
Immunoblotting Analysis 
Proteins in samples were separated by 10% SDS-PAGE and transferred 
onto nitrocellulose membranes, and the membranes were immunoblotted with 
the indicated primary antibody overnight at 4°C, washed, then incubated with the 
appropriate horseradish peroxidase-conjugated secondary antibody. After 
washing, immunoreactive proteins were visualized by using enhanced 
chemiluminescence (Pierce Biotechnology, Thermo Fisher Scientific Grand 
Island, NY, United States) and captured on autoradiographic film. Image analysis 
and quantification of protein bands was performed using NIH ImageJ (version 
number 1.48u4) and Microsoft Excel software (Office Professional Plus 2013). 
OptiPrep or Sucrose Density Gradient Subcellular Fractionation  
DRMs were prepared by density gradient centrifugation with OptiPrep or 
sucrose, as indicated, using a modification of previously described methods [18, 
38]. All procedures were carried out on ice. Briefly, four 100-mm culture dishes of 
subconfluent HEK-293T cells were treated with rPMT at the indicated 
concentrations for the indicated times. Cells were washed twice with modified 
Tyrode’s solution (20 mM HEPES, pH 7.4, containing 137 mM NaCl, 2.7 mM KCl, 
1.0 mM MgCl2, 0.18 mM CaCl2, and 5.6 mM glucose). Cells were collected and 
washed twice with the ice-cold Tyrode’s solution, then centrifuged at 1000× g for 
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10 min. The pellet was solubilized in 1 mL of lysis buffer B (50 mM Tris-HCl, pH 
7.4, containing 50 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 1.0 mM Na3VO4, 
5.0 mM Na4P2O7, and protease inhibitor cocktail, comprised of 0.2 mM 
aminoethyl-benzene sulfonyl fluoride, 1 µg/mL aprotinin, 10 µM bestatin, 3 µM E-
64, 10 µg/mL leupeptin, 2 µM pepstatin, and 50 µg/mL calpain inhibitor I). The 
cell were lysed via sonication, then incubated at 4°C for 1 h with frequent 
agitation. Cell lysates (1 mL) were mixed with 3 mL of OptiPrep or sucrose 
solution (60% aqueous iodixanol or sucrose, respectively) in a 12-mL centrifuge 
tube, and the mixture was overlaid first with 4 mL of 35% OptiPrep/sucrose 
solution diluted in STE buffer (50 mM Tris-HCl, pH 7.6, containing 50 mM NaCl, 5 
mM EDTA, and 1.0 mM Na3VO4,) and then 4 mL of 5% OptiPrep/sucrose 
solution. Ultracentrifugation was performed at 200,000× g and 4°C for 20 h using 
a Beckman SW40Ti rotor (Beckman Coulter, Inc, Indianapolis, IN, United States) 
Fractions of 1.0 mL each were collected from the top of the gradient. Total 
protein content of each fraction was quantified using Bio-Rad protein assay. The 
distribution of various proteins in the fractions was assessed by SDS-PAGE and 
immunoblotting, as described above. 
Data Analysis 
All data are presented as the mean ± standard deviation (SD) from at least 
three independent experiments, or as indicated. Unpaired two-tailed Student’s t-
test was used to determine p values. For Figures 2.4–2.6, two-way ANOVA was 
also performed using data analysis tools in Microsoft Excel for the curves of 
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control (no toxin treatment) vs. PMT-treated cells over the time course from 0 to 
6 h. Statistical significance was set at the 95% confidence level. 
 
3.3 Results 
The cytotoxic effect of PMT on cultured HEK-293T cells 
Recombinant, full-length PMT induced morphological effects in cultured 
HEK-293T cells, similar to those previously described for other cells [44]. PMT 
caused dose-dependent rounding up and clumping of cells, as shown in Figure 
3.1, and reorganization of the actin cytoskeleton (data not shown). Similar 
treatment with N-terminal (residues 1–506) or C-terminal (residues 486–1285) 
PMT fragments had no effect on cell morphology (data not shown). 
PMT treatment reduces endogenous Gαq/11 levels in detergent resistant 
membranes (DRMs) 
Because PMT acts directly on its Gα substrates and subsequent 
modulation of signaling is independent of agonist-receptor coupling to the G 
protein [1, 24, 29], I considered two possible mechanisms for PMT-mediated 
down-regulation of Gαq/11-PLCβ1 signaling: (1) PMT deamidation and activation 
of Gαq and/or Gα11 leads to degradation of the resulting constitutively active Gα 
subunit and loss of cellular levels of Gαq and/or Gα11; or (2) PMT deamidation 
and activation of Gαq and/or Gα11 leads to redistribution of the resulting 
constitutively active Gα subunit from DRMs to soluble membrane and/or cytosolic 
fractions. In agreement with a previous report [4], immunoblot analysis of total 
cell lysates using antibodies against the C-terminus of Gαq/11 showed that 
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overnight treatment of the cells with PMT did not alter endogenous protein levels 
of Gαq/11 in total cell lysates (Figure 3.2). This result did not support the first 
proposed mechanism for PMT-mediated downregulation of Gαq/11 signaling, and 
so we next considered the second possibility that the downregulation of signaling 
results from loss of the PMT-activated Gαq/11 from the membrane. Thus, I 
examined whether PMT treatment could cause loss of Gαq/11 protein from 
detergent-resistant membranes (DRMs) since many membrane signaling 
molecules are enriched in these membrane micro-domains. 
PMT-treated HEK-293T cells were lysed in the presence of detergent, and 
the cellular contents were subjected to subcellular fractionation by separation 
using Optiprep density gradient centrifugation, followed by immunoblotting 
analysis of the gradient fractions. In the density gradient centrifugation profile, 
fractions #1–7 contain low-density lipid-rich membranes and vesicles, while 
fractions #8–12 contain high-density protein-rich soluble membrane and cytosolic 
fractions [18]. As shown in Figure 3.2, whereas the abundant Gβ and Gαs 
subunits were found throughout the gradient in both higher density (#8–12) and 
lower density fractions (#4–7) from untreated control cells, the majority of the less 
abundant Gαq/11 subunits were localized to the low-density, DRM-containing 
fraction (#5), as evidenced by its co-localization with flotillin-1, a known specific 
marker for DRMs [15]. In contrast, PMT treatment resulted in the depletion of 
Gαq/11, but not Gβ or Gαs, from the DRM-containing fraction #5. With this loss 
was a concomitant increase of Gαq/11 in the soluble membrane and cytosolic 
fractions (#8–12), suggesting that PMT modification and activation of Gαq/11 
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results in the release of the active form of the Gαq/11 protein from DRMs. That 
PMT treatment did not significantly alter the levels of Gαs or Gβ in DRMs, as 
compared with flotillin-1, confirms previous findings, indicating that Gαs protein is 
not a target substrate of PMT. 
A time course revealed that while overall endogenous Gαq/11 protein levels 
in cells were not discernably affected by exposure to PMT over 12 h, the Gαq/11 
levels in DRMs were reduced by over 80% by 8–10 h in cells treated with 0.3 nM 
PMT (Figure 3.3A). This result supports the notion that PMT action on Gαq/11 
causes a redistribution of the protein, and not degradation, within this timeframe. 
By 12 h, however, the Gαq/11 levels in DRMs were restored to nearly 80% that of 
untreated cells. Again, Gβ and flotillin levels remained unaffected by PMT 
treatment. The decrease in Gαq/11 levels in DRMs was also dose-dependent, 
exhibiting an EC50 value of ~70 pM (Figure 3.3B). Although the loss of Gαq/11 
from DRMs was about 65% and 75% after 10 h of PMT treatment at a 
concentration of 320 pM and 650 pM, respectively, the Gαq/11 levels were again 
restored at higher PMT concentrations of 1.3 nM. Similar results were obtained 
using Swiss 3T3 cells (data not shown). Taken together, PMT selectively induces 
the loss of Gαq/11 proteins from DRMs in a time and dose dependent manner, 
although this loss can be masked or overcome at later times or higher toxin 
concentrations by PMT stimulation of new protein synthesis. 
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PMT treatment depletes Gαq, but not Gα11, protein levels in DRMs and the 
plasma membrane 
To distinguish the specificity of the PMT-mediated DRM depletion for Gαq 
and Gα11, we expressed exogenously either Gαq or Gα11 in HEK-293T cells over 
the endogenous background and detected the proteins using the anti-Gαq/11 
antibodies under conditions where the corresponding endogenous proteins were 
negligible (Figure 3.4A). The transfected cells overexpressing Gαq or Gα11 were 
then used to determine the effect of PMT treatment on the DRM levels of 
overexpressed Gαq or Gα11 proteins vs. Gβ. Results of immunoblot analysis of 
the DRM-containing fractions from a time course of treatment with 1.2 nM PMT 
revealed that PMT treatment caused a transient DRM depletion of Gαq (Figure 
3.4b) but not Gα11 (Figure 3.4C) after 2 h treatment.  
Considering that PMT selectively depletes Gαq and not Gα11, we 
considered the possibility that one reason we did not observe discernable 
depletion of endogenous Gαq protein levels from total cell lysates (Figures 3.2 
and 3.3) might be due to masking by the remaining Gα11 present in the 
membranes, as well as by the replacement with newly synthesized protein. We 
thus investigated the effect of PMT on Gαq and Gα11 levels in total membrane 
preparations from cells selectively overexpressing each of the proteins. As 
shown in Figure 3.5, PMT treatment caused a dose- and time-dependent 
reduction of Gαq, but not Gα11, protein levels in total membrane preparations 
from cells overexpressing the respective Gα protein. In contrast, PMT treatment 
of cells overexpressing Gα11 resulted in a slight increase in overall Gα11 protein 
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levels in membranes. However, unlike the case for DRMs, the loss of Gαq from 
membranes did not recover over the 8 h treatment period.  
To further discern specificity for PMT-modified Gαq and not Gα11 as the 
preferred target for membrane depletion, we transiently overexpressed FLAG-
tagged Gαq or FLAG-tagged Gα11 separately in HEK-293T cells and investigated 
the effect of PMT on the corresponding protein levels in DRMs. Results shown in 
Figure 3.6 are similar to those obtained in Figure 3.4. PMT caused a dose- and 
time-dependent depletion of FLAG-Gαq, but not FLAG-Gα11, from DRMs. Again, 
the effect was transient with FLAG-Gαq levels recovering by 6–8 h (Figure 3.6C). 
Also consistent with data in Figure 3.4, cells overexpressing FLAG-Gα11 showed 
no PMT-mediated loss of the protein in DRMs, and instead the protein levels 
increased slightly (Figure 3.6C). 
The catalytic activity of PMT is required for membrane depletion of Gαq 
Since PMT specifically induces the depletion of only Gαq from the 
membrane, even though Gα11 is also apparently a substrate for deamidation, we 
wanted to test whether the deamidase activity of PMT is required for the 
depletion of Gαq from the membrane. The catalytic domain of PMT possesses a 
cysteine-histidine-aspartic acid catalytic triad in the active site, where mutation of 
the cysteine residue into serine (PMT C1165S) reduces the enzymatic 
deamidase activity by 1000-fold [43]. As shown in Figure 3.7, treatment of cells 
with PMT C1165S does not result in membrane depletion of Gαq, and neither 
PMT nor PMT C1165S caused the depletion of Gα11, confirming that the 
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enzymatic activity of PMT is necessary for the depletion of Gαq from the host cell 
membrane. 
Overexpression of the constitutively active forms of Gαq either alone or in 
the presence of PMT is not sufficient to induce its depletion from the 
plasma membrane 
Since the catalytic activity of PMT is required for the depletion of Gαq from 
total membrane samples, and the consequence of PMT action renders the Gα-
proteins constitutively active, we wanted to explore whether or not constitutive 
activity of Gαq alone was sufficient to induce the depletion or exclusion of the 
activated Gαq protein from the plasma membrane. We transfected HEK-293T 
cells separately with Gαq, Gα11, or their corresponding constitutively active 
mutants, with known dominant-active mutations, Gαq Q209L and Gα11 Q209L, or 
with mutations equivalent to that introduced by PMT action, Gαq Q209E and Gα11 
Q209E (Figure 3.8A). First, we tested if overexpressing constitutively active Gα-
proteins in HEK-293T cells causes similar cytotoxic morphological effects as 
PMT treatment. Exogenous expression of Gαq or Gα11 caused little effect on 
morphology after 24 h, but, as expected, overexpression of each of the four 
constitutively active mutants of Gαq or Gα11 resulted in the rounding up and 
clumping of cells, similar to that caused by PMT treatment (Figure 3.8B).  
Unlike with the case of exogenous expression of Gαq protein, PMT 
treatment had no effect on the localization of the exogenously expressed 
constitutively active Gαq Q209E or Gαq Q209L mutant proteins in membranes 
(Figure 3.8C), suggesting that the presence of the activated form of the Gαq 
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protein alone is not sufficient to cause its removal from the plasma membrane by 
PMT. 
 
3.4 Discussion 
Work from our lab previously showed that microinjection of PMT into 
voltage-clamped Xenopus oocytes invoked a rapid (within 10 seconds) Ca2+-
dependent Cl− current, which involved activation of Gαq/11-PLCβ1 [47]. In that 
previous study, the response to PMT was transient, such that the initial strong 
response was followed by rapid downregulation and subsequent 
unresponsiveness to further stimulation by PMT. A similar initial activation and 
subsequent downregulation of PMT-stimulated Ca2+ and mitogenic signaling was 
evidenced in mammalian cells through studies involving cell cycle analysis [2, 
44]. This downregulation of Gq signaling by PMT was reminiscent of receptor-
mediated downregulation of Gq-protein signaling that occurs upon prolonged 
exposure to agonist [10, 14, 21, 30, 38, 49]; specifically, the shift of Gαq proteins 
from DRMs to detergent soluble membrane or the cytosol during agonist-
stimulated signal transduction [27]. In this chapter, we decided to explore the 
possibility that PMT-mediated activation of its Gα substrates, Gαq and/or Gα11, 
results in a similar uncoupling of the corresponding G-protein-signaling pathway.  
We considered the possibility that although PMT might have little or no 
effect on total cellular content of Gαq/11 proteins, PMT deamidation and 
subsequent activation of the Gαq/11 proteins may cause downregulation of Gq/11 
signaling through depletion of Gαq/11 levels in DRMs. The results presented here 
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show for the first time that PMT induces both dose- and time-dependent 
depletion of Gαq, but not Gα11, from lipid rafts in HEK-293T cells with the 
concomitant shift of Gαq to detergent soluble membrane fractions or the cytosol. 
Indeed, there was no significant decrease in Gαq or Gα11 observed for any of the 
time points in the control experiments with no PMT treatment or for the Gα11 
protein in the PMT-treated experiments. A transient decrease in Gαq protein 
levels was observed only in PMT-treated cells. We further showed that this PMT-
induced depletion occurs within DRM fractions from cells expressing endogenous 
levels of Gαq/11 proteins, as well as whole membranes and DRM fractions from 
cells overexpressing wildtype Gαq, and in DRM fractions from cells 
overexpressing FLAG-tagged Gαq, but not Gα11 or FLAG-tagged Gα11 proteins. 
Moreover, this PMT-mediated membrane redistribution of Gαq was dependent on 
the deamidase activity of PMT since a catalytic mutant PMT C1165S did not 
cause membrane depletion of Gαq. 
Specifically, when cellular contents of PMT-treated cells were separated 
into fractions by OptiPrep or sucrose density gradient centrifugation, we found 
that PMT treatment resulted in the loss of Gαq subunit from the flotillin-1-enriched 
DRM-containing fraction #5 with a concomitant increase of Gαq protein in the 
more soluble fractions (#8–12) of the gradient. The effect of PMT was specific for 
Gαq, and not for other Gα subunits that are not targets of PMT, such as Gαs or 
Gβ. Moreover, PMT-treatment caused membrane depletion of Gαq and not Gα11, 
even though Gαq and Gα11 share very similar structural homology and sequence 
identity of over 90%, and Gα11 can also be deamidated by PMT [12, 23]. The 
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sensitive commercially available antibody that we used in this study to detect 
endogenous protein levels recognizes the identical C-terminus of both Gαq and 
Gα11. Thus, to distinguish the specificity of the PMT-mediated DRM and 
membrane depletion for Gαq vs. Gα11, we decided to use an overexpression 
approach, where we exogenously expressed either Gαq or Gα11 and detected the 
proteins using the anti-Gαq/11 antibodies. Under these conditions, endogenous 
levels of Gαq and Gα11 were not detectable in the resulting immunoblots. 
The finding that the continued exposure to PMT was neither able to 
sustain the loss of nor perpetuate further loss of Gαq from DRMs suggests that 
the cellular Gαq levels in DRMs are replenished as a result of increased Gαq 
protein synthesis. Previous studies have shown that PMT induces protein 
synthesis and cellular proliferation in a cycloheximide-sensitive manner [28, 29]. 
This notion is supported by the slight increase (not decrease) observed for Gα11 
under similar conditions. Alternatively, it is possible that the observed 
replenishment of Gαq in the DRMs may also be due to a redistribution of the 
preexisting or newly synthesized monomeric Gαq protein that is in the membrane. 
However, unlike in the case for DRMs, the loss of Gαq from total membranes did 
not appear to replenish with time, suggesting that PMT modification and 
activation of Gαq uncouples the signaling pathway in such a way as to interfere 
with the ability of newly synthesized Gαq to interact with membranes, presumably 
through preventing re-association with Gβγ subunits and coupling to GCPRs. 
The relatively faster response times for depletion and replenishment of the 
exogenously expressed Gαq protein, compared to that observed for endogenous 
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protein, was presumably due to the increased levels of Gαq protein available as a 
substrate for PMT and to saturation of the signaling system from enhanced 
protein synthesis of Gαq encoded by the expression plasmid. Further, this PMT-
mediated loss of Gαq from DRMs and membranes is apparently masked at the 
total cell level (whole cell lysates) through redistribution to soluble membrane 
fractions or cytosol, as evidenced from the results shown in Figures 3.2 and 3.3, 
and through synthesis of new Gαq protein, which counters the overall PMT-
mediated loss of Gαq protein from membranes. 
Since overexpression of Gαq Q209E or Gαq Q209L in HEK-293T cells 
resulted in similar morphological effects as PMT treatment, we explored whether 
exogenous expression of these constitutively active mutants would lead to their 
localization in the membrane and DRMs or would also result in their membrane 
depletion. Since we found that the presence of constitutively active Gαq mutant 
proteins alone was not sufficient to induce their depletion or exclusion from 
membranes, we next considered whether PMT treatment could induce the 
removal of pre-existing constitutively active Gαq from the cell plasma membrane. 
However, we found that PMT treatment had no effect on the membrane 
localization of exogenously expressed constitutively active Gαq mutant proteins.  
Although the antibodies we used could not distinguish whether only the 
deamidated form of the Gαq is depleted from DRMs, our results clearly indicate 
the PMT catalytic activity is required. If PMT-mediated deamidation is required 
for depletion, and both Gαq and Gα11 can serve as substrates for deamidation by 
PMT [23], then PMT-deamidated Gα11 should also be depleted from DRMs. 
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However, our results (Figure 3.4C) indicate that this is not the case. This 
suggests that either cellular Gα11 is a very poor substrate for PMT and does not 
get deamidated to any significant extent during the time studied or that the as-
yet-undefined factor(s) responsible for depletion does not recognize the PMT-
deamidated Gα11 as well as the PMT-deamidated Gαq. These possibilities might 
be explored further under endogenous conditions by using antibodies that 
distinguish Gαq from Gα11 coupled with those that recognize the deamidated 
forms of the Gα proteins, such as those previously reported [12, 23]. 
These results suggest that PMT does not directly deplete the modified Gαq 
protein from the membrane, but PMT might indirectly activate an unknown 
cellular component at the membrane or expedite a cellular process responsible 
for the downregulation of membrane-associated PMT-modified Gαq. This further 
suggests that the depletion mechanism of PMT-modified Gαq proteins from the 
membrane has specificity and that PMT-catalyzed deamidation and activation of 
the Gαq protein is the not the sole signal for initiating the downregulation process. 
Whether similar membrane depletion occurs for other Gα substrates of PMT 
once they are deamidated and activated remains to be determined. 
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3.6 Figures 
 
                     
 
Figure 3.1. Effect of Pasteurella multocida toxin (PMT) on the morphology 
of HEK-293T cells. Shown are representative phase-contrast micrographs of 
HEK-293T cells treated overnight with varying concentrations of PMT: (a) no 
toxin; (b) 0.01 nM; (c) 0.07 nM; (d) 0.65 nM; (e) 1.6 nM; and (f) 3.2 nM. Bar, 10 
µm. Data shown was generated by Shuhong Luo and Mengfei Ho. 
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Figure 3.2. PMT-mediated downregulation of endogenous Gαq/11 levels in 
detergent resistant membranes (DRMs). HEK-293T cells were incubated 
without or with 0.3 nM PMT for 10 h. Preparation of cell lysates and fractionation 
by OptiPrep density gradient centrifugation was performed, as described in 
Methods Section. Each sample was separated into 12 1-mL fractions from low 
density (top, fraction #1) to high density (bottom, fraction #12), with fraction #5 
containing the DRMs, as evidenced by the presence of the DRM-specific marker 
flotillin-1. The proteins were resolved by 10% SDS-PAGE gel and subsequently 
analyzed by immunoblotting using antibodies against Gαq/11, Gαs, Gβ, and 
flotillin-1 present in the cell lysates (Lys) and fractions #4–12 from the density 
gradient. Data shown were generated by Shuhong Luo and Mengfei Ho. 
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Figure 3.3. 
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Figure 3.3. (continued) 
 
Figure 3.3. Time course and dose–response of PMT-mediated 
downregulation of endogenous Gαq/11 levels in detergent resistant 
membranes (DRMs). (A) Time course of PMT-mediated downregulation of 
Gαq/11 levels in DRMs. HEK-293T cells were incubated with 0.3 nM PMT for the 
indicated times. (B) Dose–response of PMT-mediated downregulation of Gαq/11 
levels in DRMs. HEK-293T cells were incubated with the indicated 
concentrations of PMT for 10 h. Shown are representative immunoblots of the 
lysates and the DRM-containing fraction #5 of the density gradients, prepared, 
separated by density gradient fractionation, and analyzed by immunoblotting, as 
described in Figure 2. Shown below the immunoblots are the corresponding plots 
of the quantification of the protein bands, where the data are presented as the 
mean ± SD of the relative ratio of the intensity of the Gαq/11 or Gβ bands to the 
corresponding flotillin-1 bands. Filled bars: Relative ratio of Gαq/11/flotillin-1. Open 
bars: Relative ratio of Gβ/flotillin-1. * p < 0.01; ** p < 0.001, PMT treatment vs. no 
treatment for each blot (unpaired two-tailed Student’s t-test). All data are from 
three or more independent experiments. Data shown were generated by 
Shuhong Luo and Mengfei Ho. 
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Figure 3.4. 
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Figure 3.4. (continued) 
 
Figure 3.4. PMT-mediated downregulation of Gαq and Gα11 levels in 
detergent resistant membranes (DRMs) from HEK-293T cells 
overexpressing Gαq or Gα11. (A) Shown is a representative immunoblot of 
whole cell membranes from HEK-293T cells transfected for 24 h with either no 
transfection (NT), pcDNA3.1/Gαq, pcDNA3.1/Gα11, or empty vector pcDNA3.1 
(EV). The proteins were resolved by 10% SDS-PAGE gel and subsequently 
analyzed by immunoblotting using antibodies against Gαq/11 and Gβ. (B) Time 
course of PMT-treated HEK-293T cells overexpressing Gαq. (C) Time course of 
PMT-treated HEK-293T cells overexpressing Gα11. Shown are representative 
immunoblots (bottom panels) and the corresponding quantification plots (top 
panels) of DRMs, prepared using sucrose density gradient fractionation as 
described in Methods, and analyzed as described in Figure 2. Cells 
overexpressing Gαq or Gα11 were treated without PMT (left panel) or with 1.2 nM 
PMT (right panel) for the indicated times. Proteins in the DRM-containing fraction 
#5 of the density gradient were resolved by 10% SDS-PAGE gel and analyzed by 
immunoblotting using antibodies against Gαq/11 or Gβ. Plotted data are presented 
as the mean ± SD. Filled bars: relative ratio of Gαq/11/Gβ. N is the number of 
independent experiments performed. * p < 0.05, PMT treatment vs. time 0 h for 
each blot.  
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Figure 3.5. 
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Figure 3.5. (continued) 
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Figure 3.5. PMT-mediated downregulation of Gαq and Gα11 levels in 
membrane preparations from HEK-293T cells overexpressing Gαq or Gα11. 
(A) Dose course of PMT-mediated downregulation of Gαq levels in membrane 
preparations from HEK-293T cells overexpressing Gαq treated with the indicated 
dosages of PMT for 3 h. (B) Time course of PMT-mediated downregulation of 
Gαq levels in membrane preparations from HEK-293T cells overexpressing Gαq 
treated without PMT (left panels) or with 1.2 nM PMT (right panels) for the 
indicated times. (C) Time course of PMT-mediated downregulation of Gα11 levels 
in whole membrane preparations from HEK-293T cells overexpressing Gα11 
treated without or with PMT, as in (B). Shown are representative immunoblots 
(bottom panels) and the corresponding quantification plots (top panels) of whole 
cell membranes, prepared and analyzed as described in the Methods Section. 
The proteins in the membrane fractions were resolved by 10% SDS-PAGE gel  
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Figure 3.5. (continued) 
 
and subsequently analyzed by immunoblotting using antibodies against Gαq/11 
and Gβ. Filled bars: Relative ratio of Gαq/11/Gβ. N is the number of independent 
experiments performed. * p < 0.05, ** p < 0.01, PMT treatment vs. time 0 h or 
dose 0 for each blot. 
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Figure 3.6. 
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Figure 3.6. (continued) 
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Figure 3.6. PMT-mediated downregulation of FLAG-Gαq and FLAG-Gα11 
protein levels in detergent resistant membranes (DRMs) from HEK-293T 
cells overexpressing FLAG-Gαq or FLAG-Gα11. (A) Dose–response of PMT-
treated HEK-293T cells overexpressing FLAG-Gαq were treated with the 
indicated dosages of PMT for 3 h. (B) Time course of PMT-treated HEK-293T 
cells overexpressing FLAG-Gαq were treated without (left panel) or with 1.2 nM 
PMT (right panel) for the indicated times. (C) Time course of PMT-treated HEK-
293T cells overexpressing FLAG-Gα11 treated with PMT, as in (B). Shown are 
representative immunoblots (bottom panels) and the corresponding quantification 
plots (top panels) of DRMs, prepared using OptiPrep density gradient 
fractionation and analyzed as described in Figure 2. Proteins in the DRM-
containing fraction #5 of the density gradient were resolved by 10% SDS-PAGE 
gel and analyzed by immunoblotting using antibodies against the FLAG-tag or  
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Figure 3.6. (continued) 
 
Gβ. Plotted data are presented as the mean ± SD. Filled bars: Relative ratio of 
FLAG/Gβ. N is the number of independent experiments performed. * p < 0.05, ** 
p < 0.01, PMT treatment vs. time 0 h or dose 0 for each blot. 
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Figure 3.7. Dependence of PMT-mediated downregulation of membrane 
levels of Gαq protein on the catalytic activity of PMT. HEK-293T cells 
overexpressing Gαq (left panels) or Gα11 (right panels) were treated for 2 h 
without or with 1.2 nM PMT or the catalytically inactive mutant PMT C1165S. 
Shown are representative immunoblots (bottom panels) and the corresponding 
quantification plots (top panels) of whole cell membranes, prepared and analyzed 
as described in Figure 3. The proteins in the membrane fractions were resolved 
by 10% SDS-PAGE gel and subsequently analyzed by immunoblotting using 
antibodies against Gαq/11 or Gβ. Plotted data are presented as the mean ± SD. 
Filled bars: relative ratio of Gαq/11/Gβ. N is the number of independent 
experiments performed. ** p < 0.01, PMT treatment vs. no treatment for each 
blot. 
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Figure 3.8. 
 
A 
 
 
             
 
 
 
 
B 
 
 
                      
 
  
NT EV 1.2nM PMT 
Gq GqQ209E GqQ209L 
G11 G11Q209E G11Q209L 
 105 
 
Figure 3.8. (continued) 
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Figure 3.8. Morphology of HEK-293T cells exogenously expressing 
constitutively active Gα-proteins and the effect of PMT on membrane levels 
of constitutively active Gαq proteins. (A) Representative immunoblots of 
membrane preparations of HEK-293T cells overexpressing Gαq, Gα11, or their 
constitutively active Q209E and Q209L counterparts, using antibodies against 
Gαq/11 or Gβ. Control membranes were from cells transfected with empty vector 
pcDNA3.1 (EV). (B) Shown are phase-contrast micrographs of HEK-293T cells 
overexpressing the indicated Gα-protein, or without or with 1.2 nM PMT 
treatment, as indicated. NT, no transfection or treatment. Bar, 200 µm. (C) 
Representative immunoblots of membrane preparations showing protein levels of 
Gαq Q209E, Gαq Q209L, or Gβ in cells without or with 1.2 nM PMT treatment for 
3 h PMT. Shown above the immunoblots are the corresponding plots of the 
quantification of the bands, where data are presented as the mean ± SD of the  
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Figure 3.8. (continued) 
 
relative ratios of Gαq/11/Gβ. N is number of independent experiments performed. 
p > 0.6, PMT treatment vs. no treatment for each plot. 
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Chapter 4 
Harnessing the talents of the escape artist:  
Conclusions, impact, and implications 
 
 
4.1 A more complete model of PMT cellular intoxication 
 
The work presented in the second chapter of this thesis further reinforces 
that PMT-N is the cytosolic delivery vehicle for C-terminal cargo and plainly 
shows that its native cargo is delivered intact from late endosomes as C1-C2-C3, 
with its MLD in tow. From the results of this investigation, we have gained further 
insight into the determinants of deliverable cargo subdomains; namely, that the 
intrinsic nature of the cargo is important for delivery. This encourages us to 
rethink protein modularity outside of just the biochemical or enzymatic activities 
associated with individual cargo subdomains and to perhaps ascribe multi-
subdomain or holo-domain function to cargo segments in terms of the cytosolic 
delivery process or other potential roles they may play.   
With PMT-N being able to deliver various types of cargo, including GFP [4, 
16], diphtheria toxin catalytic domain [2], C1-C2, and C1-C2-C3 without or with 
truncated C3 modules, but not C3 alone invites one to infer the unforeseen role 
of C1-C2 as a multi-domain functional unit for assisting in the delivery of C3. It is 
possible that cargo like C3 may require help to translocate across the endocytic 
membrane, and that C1-C2 may function as a chaperone of sorts to work in 
concert with the N-terminus to deliver C3 into the cytosol. Minimally, C1-C2 may 
stabilize the C-terminus for efficient cytosolic delivery. In either case, additional 
data from this thesis work suggests that PMT-C3 without C1-C2 becomes 
trapped inside of endosomes (Figure 4.1), and that C3 is only delivered into the 
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cytosol when C1-C2 is present (Chapter 2, Figure 2.6). Considering PMT-N as 
the delivery vehicle, and C3 a subdomain cargo, then C1-C2 can possibly be 
considered the cargo “trailer” that aids in the delivery of the C3 activity cargo. 
Ultimately, this informs us that certain cargo subdomains may not be delivered 
without specific discrete subdomain partners. This furthers our understanding of 
the cytosolic cargo delivery process and may be applicable to other related A-B 
type toxins.  
The findings in the third chapter of this thesis demonstrate that PMT 
modification of Gaq and its subsequent activation leads to the redistribution of 
Gaq within membranes and depletion of Gaq from the plasma membrane as a 
possible mechanism of downregulating GPCR-Gaq-PLCb1 signaling, which may 
be a phenomenon that also applies to other heterotrimeric Ga-protein targets of 
PMT. Additionally, this may occur with other protein toxins that target 
heterotrimeric G-proteins; offering insights into the intoxication effects of PMT 
and related toxins in various cells types. The biochemical mechanism by which 
PMT induces G-protein removal from the membrane is not understood. It is 
unclear if PMT does this directly; if this is the result of the previously 
characterized natural phenomenon of desensitization that occurs in cells to 
prevent or curb G-protein signaling overstimulation [11]; or if a novel 
undiscovered pathway of intracellular negative feedback may be involved. Many 
of the known examples of G-proteins being downregulated to diminish signaling 
are GPCR and/or agonist mediated  [5, 6, 7, 8, 12, 15, 17, 18, 21, 26] and these 
have been shown to occur within different time frames and cell types and seem 
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to be dependent upon the agonist used. Indeed, examples include the 
phenomenon where the GPCR may or may not be downregulated as well. All of 
this, coupled with PMT’s ability to induce downregulation of G-protein-mediated 
signaling pathways [ 3, 9, 10, 13, 24, 25], suggests that a system of redundant 
mechanisms exist for G-protein downregulation. Perhaps, different cell types 
invoke different mechanisms or variations on the same mechanism to accomplish 
the dampening of G-protein signaling. Elucidation of these potentially different 
mechanisms or variations thereof remains to be explored. 
I sought to address if PMT caused direct or induced depletion of Gaq from 
the plasma membrane. I designed a series of in-vitro assays that took plasma 
membrane samples obtained through fractionation of cells that transiently 
overexpressed Gaq and subjected them directly to PMT or the C-terminal cargo 
of PMT, C1-C2-C3 (PMT-C) (Figure 4.2). In all cases, I could not detect any 
depletion of Gaq from plasma membrane samples. Perhaps more 
experimentation and optimization for this assay is needed, but this preliminary 
data suggests that PMT does not directly deplete Gaq from plasma membranes 
and that other cellular components or co-factors may be required for depletion. 
With work generated in this dissertation and others, we now have a more 
complete model of the PMT cellular intoxication process that fills in the 
knowledge gaps pertaining to the major questions presented in the first chapter 
of this thesis (Figure 4.3). We can indubitably state that upon binding the cell-
surface receptors of phosphatidylcholine, sphingomyelin, and an unknown 
protein partner, full-length PMT is taken up by endocytosis and is trafficked from 
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early to late endosomes in an Arf6-dependent manner. Upon the lowering of the 
endosomal pH, instead of being trafficked to the lysosomal degradative pathway, 
the ER, or the Golgi, acidification of PMT-N likely triggers conformational 
changes and membrane interactions that facilitate the translocation of the C-
terminal cargo across the endocytic membrane into the cytosol. During this 
process, it is likely C1-C2 first translocates across the endocytic membrane and 
subsequently pulls C3 through into the cytosol. The translocated intact C1-C2-C3 
is cleaved near the MLD of C1 and the MLD helps to localize the intact C1-C2-C3 
to the plasma membrane, bringing the catalytic subdomain C3 into proximity of 
its target Gα subunit. PMT constitutively activates the Gα subunit via 
deamidation, whereby the Gα then acts upon its target effector. Subsequent to 
activation, PMT-modified Gα is redistributed and eventually removed from the 
membrane, resulting in uncoupling and downregulation of the GPCR-G-protein 
signaling pathway, as was shown in chapter 3 of this thesis. 
 
4.2 PMT: Its role in pathogenesis and the development of novel 
therapeutics 
 
Findings in this thesis have broader implications on how we understand 
the structural packaging and functioning of A-B type protein toxins; both in terms 
of their endosome-to-cytosol translocation and use as vehicles to deliver 
exogenous cytosolic cargos into host cells. These findings also offer insights on 
the inherent dual functions of toxins to affect signaling and alter cell fate to 
promote infection by their cognate organisms.  
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Exogenous cargo delivery by different A-B type toxins opens doors for 
their potential use as pharmacological tools to deliver powerful novel therapeutics 
into unhealthy cells as a way of treating or curing human illnesses and ailments, 
such as cancer, hypertension, and chronic pain relief [reviewed in 14]. Indeed, 
such studies are underway and are geared primarily at exploiting the modularity 
of protein toxins [reviewed in 1, 23]. Now that we have a deeper understanding of 
PMT cargo translocation and cytosolic delivery from work in this thesis and that 
of others, we can confidently say that PMT-N is a viable candidate for future 
study with regard to its potential use as a novel therapeutic in drug delivery of 
enzymatic and non-enzymatic proteinaceous cargo. Furthermore, this thesis 
informs the possible existence of other “cargo trailers” like C1-C2, that may be 
required for or used to possibly enhance cargo subdomain delivery. That very 
notion must play a role to some degree in the minds of pharmacologists, protein 
engineers, and toxin biologists when studying the effects of cargo delivery into 
host cells and when designing unique proteins with different functions that they 
wish to have carried out intracellularly. 
Defining the signaling dynamics of the activity cargos of modular A-B 
toxins further gives way for their potential use as the novel toxin-based cytosolic 
therapeutics, especially in cases where specific abnormal cell types may require 
targeted killing or inhibition of proliferation. PMT-induced signaling modulation 
can ultimately end in cell death, cell differentiation, or proliferation [reviewed in 
22]. Since we know that PMT uncouples and downregulates Gq and Gi signaling, 
we can foresee how downregulation of these pathways may affect cellular fate. 
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For example, activation of Gq signaling will typically lead to cells going down a 
mitogenic pathway, remaining anti-apoptotic, and undergoing proliferation. If cells 
are exposed to PMT, there is a significant chance that since PMT is able to first 
activate, but then downregulate Gaq, that the cell may subsequently go down an 
anti-proliferative path which may lead to cell differentiation or cell death (Figure 
4.4). The initial activation and then reversal of signaling outcomes for Gi signaling 
is a possibility, as well. Where Gai normally helps keep cell differentiation in 
check, now as a result of PMT-induced downregulation, the fate of the cell could 
end in unwanted differentiation (Figure 4.4).  
Certainly, all G-protein signaling pathways targeted by PMT will be nearly 
acted upon simultaneously, so the resulting outcomes from those G-proteins that 
are influenced will not be so simple. Therefore, the ultimate cellular fate will 
depend a great deal on cell type (tissue tropism), the prevalence of certain G-
proteins expressed, and the duration and magnitude of PMT-induced signaling 
and subsequent downregulation of that signaling. The extent of crosstalk 
between signaling pathways is also important. Indeed, as previously discussed, 
cellular fate is important to disease states, such as in atrophic rhinitis, where it 
has been shown to be mediated by Gq signaling in dictating the differentiation of 
the pre-osteoclast cell lineage into osteoclasts, and preventing 
osteoblastogenesis [19, 20]. Given this, it is important to know how PMT-C may 
affect cells targeted by its use in future therapeutics for the achievement of 
certain cellular outcomes in unhealthy cells and to intricately understand its role 
in pathogenesis. Therefore, downregulation of G-protein signaling is just as 
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important to study or to consider in PMT-mediated cellular intoxication where 
PMT’s ultimate role in toxin-mediated diseases is to dictate or influence cellular 
fate through its modulation of intracellular signaling. 
4.3 Final Remarks 
Protein toxins and effectors are simply amazing and perhaps the most 
dangerous yet potentially useful tools that we study in the biological/biochemical 
sciences. I have been in love with the notion of experimenting with them since 
my undergraduate days at UIUC when I first heard about cholera toxin and 
pertussis toxin and their action on G-protein signaling pathways from Dr. Abigail 
Salyers and Dr. Jack Ikeda in MCB 300. I have been fortunate to live out my life’s 
dream of becoming scholar in studying and characterizing one of them. If my 
good fortune continues…I’ll be examining more of them and the affect they have 
on human and animal life for the rest of my existence!  
Again, thank you to all who had a hand in helping me achieve my dream. 
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4.4  Figures 
 
 
 
 
Figure 4.1. Immunoblot profile obtained from subcellular fractionation of Swiss-
3T3 cells treated with 5 µM PMT-C3 for 18 hours.  
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Figure 4.2. PMT direct G-protein depletion Assays. Top Panel: Cells 
transfected with Gαq-protein, membranes harvested from them and solubilized 
using supernatants of untransfected cells. Incubated with PMT for 2 hours and 
pelleted membrane were resolved on SDS-Page and subsequently  
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Figure 4.2. (continued) 
immunoblotted. Middle Panel: Cells transfected with Gαq-protein, membranes 
harvested from them and solubilized using supernatants of untransfected PMT-
treated cells. Incubated with PMT for 2 hours and pelleted membrane were 
resolved on SDS-Page and subsequently immunoblotted. Bottom Panel: Cells 
transfected with Gαq-protein, membranes harvested from them and solubilized 
using PBS. Incubated with PMT-C for 2 hours and pelleted membrane were 
resolved on SDS-Page and subsequently immunoblotted. The left side of all 
panel show a procedural schematic. The right side of all panels show immunoblot 
analysis results. 
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Figure 4.3. Updated Model of PMT Cellular Intoxication. PMT is taken up by 
endocytosis and is trafficked from early to late endosomes in an Arf6-dependent 
manner. Upon the lowering of the endosomal pH, instead of being trafficked to 
the lysosomal degradative pathway acidification of PMT-N likely triggers 
conformational changes facilitate the translocation of C-terminal cargo across the 
endocytic membrane. C1-C2 first translocates across the endocytic membrane 
and subsequently pulls C3 through into the cytosol. The translocated intact C1-
C2-C3 is cleaved near the MLD of C1 and the MLD helps to localize the intact 
C1-C2-C3 to the plasma membrane, bringing the catalytic subdomain C3 into 
proximity of its target Gα subunit. PMT constitutively activates the Gα subunit via 
deamidation, whereby Gα then acts upon its target effector. Subsequent to 
activation, PMT-modified Gα is removed from the membrane, resulting in 
uncoupling and downregulation of the GPCR-G-protein signaling pathway. 
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Figure 4.4. Simplified model of G-protein influenced cellular fate. PMT 
induced downregulation of G-proteins may lead to opposing signaling outcomes 
and cell fate. The 1st and 3rd columns show the expected cellular outcomes of 
normal G-protein signaling. The 2nd and 4th columns show the potential opposing 
outcome of downregulated signaling as caused by PMT.  
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